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ABSTRACT 
Malaria is one of the oldest diseases know to mankind, still having devastating consequences; 
killing 1 million people/year. The efforts to control this disease have been focused on the 
control of its transmission and, most importantly, its clinical management by effective 
chemotherapy. Concerning the latter, several antimalarials have been developed in the last 
decades. They can be subdivided into four structural classes: aminoquinolines, antifolates, 
artemisinin derived compounds and naphtoquinones. Although reasonably well studied in 
pharmacokinetics aspects, very few data is available concerning their effects in the gene 
expression regulation system. This is particularly relevant concerning the xenosensors PXR 
and CAR. 
In a first part, this project aimed to elucidate the capacity of currently used antimalarials and 
their main known metabolites to activate the PXR/CAR system. For this purpose, mammalian 
two hybrid and gene reporter assays, together with induction studies in primary human 
hepatocytes were performed.   
For PXR and CAR we could observe activation, by compounds from the artemisinin family 
(artemisinin, arteether, artemeether, deoxy-arteether and deoxy-artemisinin) both in vitro and 
in primary human hepatocytes, corroborated by the induction of prototypical target genes. A 
repression by artesunate of key targets genes, CYP3A4 and CYP2B6 was observed by this 
compound in primary hepatocytes, confirming the observed inhibition in vitro of the 
induction of both PXR and CAR.  
Further activation of PXR by the aminoquinolines, lumefantrine, carboximefloquine, 
amodiaquine, DEAQ and chloroquine, was observed in the in vitro system. Amodiaquine also 
induced CAR in the in vitro system.  From the aforementioned compounds only 
carboximefloquine, consistently induced the induction of CYP2B6 in the hepatocytes, 
indicating a promoter specific activity. Both amodiaquine and DEAQ showed a repression of 
CYP3A4 and CYP2B6, indicating that although they may induce the interaction of PXR with 
its co-activators, they may not be able to induce the release of co-repressors. 
 The present data is of particular interest regarding the pivotal role of artemisinins and 
aminoquinolines in the current worldwide WHO supported artemisinin combination therapies 
(ACT), the first line treatment currently recommended. Future evidence based developments 
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of this therapy can benefit from this data on the high probability of induction of this two gene 
expression systems by ACT components, and its drug-drug interactions. 
The second part of this project focused on the study of the genetic basis of variability of PXR 
dependent induction of key CYP450 upon exposure to artemisinins. The project was based on 
a previously study in 75 Vietnamese subject (Asimus et al., 2007), where metabolic ratios for 
a number of pivotal PXR/CAR inducible CYPs (e.g. CYP3A4, CYP2C19) were determined 
upon artemisinin compounds exposure. For this purpose the promoter region, exons and exon-
intron boundaries of the PXR gene were re-sequenced for every subject. This approach 
allowed the identification of 32 SNPs, six of them described for the first time. Overall, we 
could observed an increased prevalence of the minor allele for the polymorphisms 252 /275 
A>G and 10331 A>G, 10483 T>C in the group of higher inducers. Further analysis of these 
SNPs in primary human hepatocytes showed a higher CYP3A4 mRNA induction in the 
carriers of the wt/wt genotype. This is an indication that different distribution of the allele in 
the high and low inducers group is not influencing directly the expression of CYP3A4. 
Taken together we could confirm some of the data published concerning phenotypic changes 
induced by PXR SNPs. However no clear results were obtained for the newly identified SNPs 
due to a reduced number of samples, except for the SNP F420Y. 
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ZUSAMMENFASSUNG 
Malaria ist eine der ältesten Krankheiten der Menschheit, mit immer noch verheerenden 
Folgen; jedes Jahr sterben an ihr weltweit 1 Million Menschen. Die Anstrengungen zur 
Bekämpfung der Krankheit konzentrieren sich zum einen auf die Unterbindung ihrer 
Übertragung und zum anderen auf eine effektive Arzneimitteltherapie. Zahlreiche 
Malariatherapeutika wurden in den letzten Jahrzehnten entwickelt. Sie werden in vier 
strukturelle Klassen unterteilt: Aminochinoline, Antifolate, Artemisinin-Derivate und 
Naphtochinones. Während pharmakokinetische Aspekte der Malariatherapie vergleichsweise 
gut untersucht sind, ist nur wenig darüber bekannt, inwieweit diese Arzneimittel die 
Regulation der Genexpression arzneimittelabbauender Enzyme und von 
Arzneimitteltransportern beeinflußen. Dies ist insbesondere hinsichtlich der Aktivierung der 
Fremdstoffsensoren PXR und CAR, welche die Induktion dieser Enzyme und Transporter 
vermitteln, von Interesse. 
In ersten Teil dieser Arbeit wurde daher untersucht, ob die zurzeit eingesetzten 
Antimalariatherapeutika und ihre wichtigsten Metabolite die Fremdstoffsensoren PXR und 
CAR aktivieren. Zu diesem Zweck wurden „mammalian two-hybrid“ und Reportergen-
Studien durchgeführt. Desweiteren wurde untersucht, ob diese Substanzen die Expression 
arzneimittelabbauender Enzyme und Transporter in primären, menschlichen Hepatozyten 
induzieren.   
Für die meisten Substanzen aus der Artemisinin-Familie (Artemisinin, Arteether, Artemether, 
Deoxyarteether und Deoxyartemisinin) konnte eine Aktivierung von PXR und CAR in vitro 
beobachtet werden. Diese Befunde wurden durch die Induktion prototypischer Zielgene von 
PXR und CAR in mit diesen Substanzen behandelten primären Hepatozyten bestätigt. Im 
Gegensatz hierzu reprimiert Artesunat die Expression wichtiger Zielgene, wie CYP3A4 und 
CYP2B6, in primären Hepatozten, welches die in vitro beobachtete Hemmung der 
Aktivierung von PXR und CAR bestätigt.  
Weiterhin aktivierten die Aminochinoline Lumefantrin, Carboximefloquin, Amodiaquin, 
DEAQ und Chloroquin PXR im in vitro System. Amodiaquin aktivierte zusätzlich CAR. Von 
den genannten Substanzen induzierte nur Carboxymefloquin die Expression von CYP2B6 in 
entsprechend behandelten primären Hepatozyten, was auf eine Promotor-spezifische Aktivität 
des Carboxymefloquin-aktivierten PXR hinweist. Amodiaquin und DEAQ reprimierten in 
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primären Hepatozyten die Expression von CYP3A4 und CYP2B6.   Dies läßt vermuten, dass 
diese beiden Substanzen, obwohl sie die Interaktion von PXR mit seinen Ko-Aktivatoren 
induzieren, nicht die an PXR gebundenen Ko-Repressoren freisetzen können.  
Diese Ergebnisse sind, angesichts der zentralen Rolle der Artemisinine und Aminochinoline 
in der zurzeit von der WHO zur Behandlung der Malaria hauptsächlich empfohlenen 
Artemisinin-Kombinationstherapie (ACT), von besonderem Interesse. Für die zukünftige 
Weiterentwicklung der ACT könnten die hier gewonnenen Ergebnisse zur Aktivierung von 
PXR und CAR und eventuell darausfolgende Arzneimittelinteraktionen von Bedeutung sein.  
Im zweiten Teil dieser Arbeit wurde versucht, genetische Ursachen der ausgeprägten 
interindividuellen Variabilität der PXR-abhängigen Induktion wichtiger Zytochrom-P450-
Enzyme durch Artemsinine zu ermitteln. Die Untersuchung basiert auf einer kürzlich 
durchgeführten klinischen Studie an 75 Vietnamesen (Asimus et al., 2007), in der die 
metabolischen Aktivitäten einiger wichtiger PXR/CAR-induzierbarer Zytochrom-P450-
Enzyme (z.B. CYP3A4, CYP2C19) nach Behandlung mit Artemisininen bestimmt wurden. 
Zu diesem Zweck wurden die Promotor-Region, alle Exons und Exon-Intron-Übergänge des 
PXR-Gens in allen an der klinischen Studie teilnehmenden Individuen vollständig 
sequenziert. Dieser experimentelle Ansatz ermöglichte die Identifizierung von 32 genetischen 
Polymorphismen, von denen sechs hier zum ersten Mal beschrieben werden. Die PXR-
Polymorphismen 252/275 A> G, 10331 A> G und 10483 T> C waren mit einer stärkeren 
Induktion der CYP3A4 Aktivität assoziiert. Genau der gegenteilige Effekt wurde jedoch bei 
der Untersuchung der Induktion der CYP3A4 Expression durch Artemisinin in primären 
menschlichen Hepatozyten beobachtet. Dies weist daraufhin, dass diese PXR-
Polymorphismen die Expression von CYP3A4 wohl nicht direkt beeinflußen.  
Zusammenfassend, konnten in diesem zweiten Teil der Arbeit einige bereits publizierte 
Assoziationen von PXR-Polymorphismen mit phänotypischen Veränderungen bestätigt 
werden. Hinsichtlich einer Assoziation mit dem Ausmaß der Induktion, wurden für die neu 
identifizierten Polymorphismen jedoch keine eindeutigen Ergebnisse erzielt, was vermutlich 
auf eine zu kleine Probenzahl zurückzuführen ist. Lediglich der Polymorphismus, der zu der 
neuen PXR Proteinvariante F420Y führt, ist eindeutig mit einer sehr schwachen Induktion 
verbunden.  
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1. INTRODUCTION 
 
1.1. MALARIA 
Malaria has devastating consequences: it strikes over 250 million people worldwide and kills 
near 1 million people each year, many of whom being children under 5 years of age (Eastman 
and Fidock, 2009). This disease is transmitted in 109 countries spread throughout Africa, 
Asia, Oceania, and Latin America, with special incidence in Sub-Saharan Africa, where more 
than 90% of the cases occur (Sachs, 2005; WHO, 2009). 
Although one of the oldest diseases known to Mankind, descriptions of this disease are found 
in ancient Roman, Chinese, Indian and Egyptian manuscripts, it was only in the 19
th
 century 
that the mosquito Anopheles was identified as the vector of this disease. This discovery was 
described by Ronald Ross. At the same time the protozoans from the genus Plasmodium 
responsible for the disease were identified by Charles Louis Alphonse Laveran (Cox, 2010). 
These two breakthroughs were distinguished by the earning of two physiology or medicine 
Nobel prizes, respectively in, 1902 and 1907.   
Presently five species of Plasmodium are known to infect the human species, namely, 
Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium falciparum, and 
the recently identified Plasmodium knowlesis (White, 2008).  
For millennia human societies have been trying to control this disease. The efforts in the last 
60 years have been strongly focused on two strategies – vector control, trying to reduce the 
populations of host mosquitoes (and hence the transmission of the disease) and effective 
chemotherapy.  At both fronts, the development of drug resistance to insecticides by the 
vector and against antimalarial drugs by the parasite, have curtailed these efforts (Ollomo et 
al., 2009).  
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1.1.1. PLASMODIUM LIFE CYCLE 
Plasmodium parasites have an intricated life cycle, comprising two main stages: an exogenous 
sexual phase in the mosquito (Sporogony) and an endogenous asexual phase in the human 
host (Schizogony) (Fig.1). These stages are similar in all species, varying mainly in the 
duration of the Schizogony phase. 
 
Figure 1: Plasmodium life cycle. The life cycle comprehends one sexual stage in the mosquito (C), and two 
stages in the human host, a liver stage also known as exo-erythrocytic cycle (A) and a blood stage, the 
erythrocytic cycle (B) (http://www.dpd.cdc.gov/dpdx/HTML/ImageLibrary/Malaria_il.htm, accessed 01 April 
2010).  
 
The infection starts by the injection of the human host with sporozoites together with the 
saliva of a feeding mosquito (Fig.1). This sporozoites migrate in the blood stream to the liver, 
were the parasite will undergo a first asexual replication. In the liver cells, the parasite will 
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pass through different forms culminating with the production of merozoites (invading forms) 
that are released to the blood stream where they will invade erythrocytes. In these cells the 
merozoites will develop to immature trophozoites, progressing to mature trophozoites or 
gametocytes.  This maturation is accompanied by an active metabolism including the 
ingestion of host cytoplasm and proteolysis of hemoglobin into amino acids. The erythrocyte 
phase will end with the rupture of the cell, and the release of new merozoites that can invade 
new erythrocytes. In a separate development program a small fraction of this intra-erythocytic 
cycling population will become gametocytes. These sexual forms are able to continue the life 
cycle of the parasite (now including a recombination step through meiosis) inside the 
mosquito gut, upon their ingestion by the vector. The aforementioned rupture of red blood 
cells is the cellular event responsible for the intermittent fever symptoms of the pathology.  
For P.malariae the periodicity is 72h of the cycle (and hence the fever periods), for 
P.falciparum, P.ovale and P.vivax is a 48h cycle, while P.knowlesi presents a shorter 24h 
cycle (Singh et al., 2004). 
In the mosquito the female and male gametocytes, ingested during the mosquito blood meal, 
will form a zygote in the insects mid gut. The zygote will then suffer meiosis and develop into 
the ookinete. This form of the parasite will then migrate from the blood meal to the cells of 
the intestinal wall of the mosquito forming an oocyst. This oocyst will undergo several rounds 
of asexual replication, during a period of 10-14 days resulting in the production of thousands 
of sporozoites that will migrate to the mosquito’s salivary gland waiting for the next blood 
meal of the insect, and hence, to be transmitted to a new vertebrate host (Aly et al., 2009).  
 
1.1.3. MALARIA TREATMENT  
Quinine and artemisinin – the chemical precursors of the present antimalarials 
Chemotherapy is the main strategy for the control of malaria, particularly in the perspective 
that a fully effective malaria vaccine for the uncomplicated forms of the disease is most likely 
decades ahead for the endemic region populations. 
The first malaria chemotherapy known to Western populations emerged in the XVII century. 
An extract from the bark of the chinchona trees from Peru, used by the local Peruvian Indians 
populations for the treatment of fevers came to the attention of the Jesuit priests operating in 
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these regions. This powder was brought to Europe by this congregation, gaining its common 
name- Jesuit Bark. It was only in 1820 that the French chemists Joseph Pelletier and Jean 
Biename Caventou identified quinine as the active compound in the chinchona bark powder 
(Schlitzer, 2007). 
Although unknown by the Europeans, the Chinese medicinal herb Artemisia annua is most 
likely the oldest documented antimalarial chemotherapy. The anti-fever properties of teas 
prepared with this type of plants were first described in the fourth century A.D. by Ge Hong. 
The information on these documents was taken to full advantage in the XX century as a 
guideline for the discovery of the artemisinin class of sesquiterpenes by the Chinese academy 
of militar sciences during the Vietnam War (Li and Wu, 2003).  
Both artemisinin and quinine led to the production of several new synthetic or semi-synthetic 
antimalarials, forming the basis of the majority of the presently available antimalarial drugs 
(Cui and Su, 2009). 
The currently available antimalarials can be subdivided in four classes: aminoquinolines, 
antifolates, artemisinin derived drugs and most recently, the napthoquinones (e.g. 
atovaquone). 
The success of these drugs depends mainly from on the interactions between the drug and the 
parasite and on interactions between the antimalarials and the human host. This thesis will 
focus on these last interactions, with particular focus on possible drug interactions between 
the antimalarials with other used drugs. The characteristics of currently available antimalarials 
will be described in the next chapter. 
 
1.1.3.1. QUINOLINES 
This group of antimalarials comprises compounds derived from the quinine structure. It may 
be subdivided in 4-aminoquinolines (e.g. chloroquine and amodiaquine), 8-aminoquinolines 
(Primaquine) and aminoquinoline alcohols (mefloquine, lumefantrine, halofantrine and 
quinine). Their structures are shown in figure 2.   
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Quinine  
Quinine is a second line antimalarial used normally in combination with an antibiotic to treat 
uncomplicated P. falciparum malaria. It may also be used as first line for the treatment of 
pregnant women particularly in the first trimester, travelers returning to non-endemic 
countries and for the treatment of severe malaria. A 7 day treatment regimen starting with an 
initial dose of 20 mg/kg of body weight followed by a maintenance dosage of 10mg/kg body 
weight each 8 h is necessary to achieve full recovery (WHO, 2010). Recently, quinine is also 
emerging as a second line of choice in several national malaria control programmes 
(http://malaria.who.int/treatmentpolicies.html). 
This drug acts mainly in the mature trophozoite stage of the parasite development. It may also 
kill the sexual stages of P. vivax, P.malariae and P.ovale. Its antimalarial action it thought to 
be related with the inhibition of the parasite haem detoxification in the food vacuole (Famin 
and Ginsburg, 2002). In the human host, quinine is metabolised to its primary active 
metabolite, 3-hydroxyquinine, by CYP3A4/5. The formation of its minor metabolites (10S)-
11-dihydroxy-dihydroquinine, 2L-quininone and (10R)-11-dihydroy-dihydroquinine is 
dependent on CYP3A4 and CYP2C9 activity, respectively (Kerb et al., 2009). 
Despite being one of oldest antimalarials available, quinine, is one of the few with only very 
rare cases of clinical resistance. The first reliable clinical reports of quinine resistance 
occurred 100 years ago in Brazil, among non-immune immigrants involved in railway 
constructions in the West of the country (Neiva, 1910). Since then, only sporadically 
resistance to this compound has been reported in South-East Asia and Western Oceania 
(WHO, 2006). This may be due mainly to the short half life of the compound, not allowing a 
window of low dose selection, and to the fact that quinine has been only used as a 
second/third line antimalarial.  
 
Chloroquine  
The original synthesis of chloroquine was performed in 1934 by the hands of H. Andersag 
and co-workers at the I.G. Farbenindustrie AG laboratories under the name of Resochin
®
. At 
the time it was determined as too toxic for human use and ignored until the World War II. At 
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this time, the United States launched a national program for the discovery of new 
antimalarials. A substance coded SN-7619 was uncovered upon large compound surveys; that 
revealed to be identical to the previous Resochin
®
. This was renamed as chloroquine (CQ). At 
this time clinical trials showed that CQ had a therapeutic value as an antimalarial, without any 
major side effects. It reached the pharmaceutical market in 1947 as a prophylaxis agent 
(Jensen and Mehlhorn, 2009).  
Chloroquine is currently being used as a monotherapy or in combination with primaquine in 
the treatment of chloroquine sensitive P.vivax, P.malariae and P.ovale malaria, at a dosage of 
25 mg base/kg body weight over 3 days. This drug is also used in the treatment of 
uncomplicated P.falciparum malaria in some Indian provinces and central America/Caribbean 
(WHO, 2010). This is the best characterized quinoline antimalarial – in terms of mechanism 
of action; research in this drug has set the current model that this type of compounds exert its 
action through the inhibition of the process of haem detoxification in the food vacuole of the 
parasite (Hempelmann, 2007). 
In the human host, chloroquine is biotransformed to its metabolites, N-desethylchloroquine, 
bisdesethylchloroquine, 7-chloro-4-aminoquinoline, chloroquine side-chain N-oxide, and 
chloroquine di-N-oxide by the action of CYP2C8, CYP3A4/5, and to a lesser extent CYP2D6 
(Kerb et al., 2009).   
Resistance to chloroquine has widespread, with the exception of some regions in Central 
America and the Caribbean, starting only a few years after its introduction in Thailand and 
Colombia (Young et al., 1963). 
 
Amodiaquine  
Amodiaquine was patented in the 1940s by the pharmaceutical corporation Parke Davis 
(Burckhalter et al., 1948). Used in prophylaxis it was correlated with rare but severe cases of 
agranulocytosis and hepatotoxicity (Meshnick and Alker, 2005). Despite the initial reported 
side effects, amodiaquine has been introduced in areas with high incidence of chloroquine 
resistance, without any major reported side effects and considerable efficacy (WHO, 2006; 
Ursing et al., 2007; Martensson et al., 2005). 
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Presently this drug is widely used in many regions, namely in Africa, combined with 
artesunate, for the treatment of uncomplicated P.falciparum malaria. Treatment with this drug 
involves a 3 day regimen of co-formulated artesunate and amodiaquine, in a daily intake of 
4mg/kg artesunate and 10 mg/kg day amodiaquine (WHO, 2010). Being a member of the 4-
aminoquinoline class, amodiaquine is structurally and functionally related with chloroquine. 
Resistance to this drug used as monotherapy was early documented. The first descriptions 
were published in the 1960s in Colombia (Young, 1961). These phenomena did not expand as 
rapidly as with CQ, possibly due to its less frequent use. 
Amodiaquine is metabolised to it active metabolite, N-desethylamodiaquine mainly by 
CYP2C8 in the liver, and most likely by CYP1A1 and CYP1B1 in extra-hepatic tissues (Gil, 
2008). 
 
 
Figure 2: Structures of the quinolines. 
Mefloquine 
Quinine 
Chloroquine Amodiaquine 
Primaquine Lumefantrine 
Halofantrine 
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Primaquine 
Primaquine was first synthesized in the US in 1946. This 8-aminoquinoline is still the only 
available antimalarial that targets hypnozoites – the dormant forms of P. vivax in the liver. Its 
mechanism of action is still unknown. Although effective, this antimalarial has been 
associated with severe side effects, e.g. haemolytic anaemia. During the last years efforts to 
develop equivalently effective antimalarials not associated with these severe side effects have 
output two new primaquine analogues aablaquine and tafenoquine, both already in final 
stages of clinical trials against P.falciparum and P.vivax (Vale et al., 2009).  
This drug is still mainly used as a radical treatment for P.vivax malaria, given once a day for 
14 days at a dosage ranging from 0.25-0.50 mg/kg/day (WHO, 2010).  
Primaquine is primarily metabolized to carboxyprimaquine by CYP1A2, CYP3A4 and by the 
monoamine oxidase. This metabolite is thought to be responsible for its toxicity (Kerb et al., 
2009). 
 
Mefloquine  
Mefloquine is a synthetic analogue of quinine, developed in the 1970s at the Walter Reed 
army institute of research in the USA as a response to the chloroquine resistant malaria 
burden in the US troops engaged in the Vietnam War (Modell, 1968; Powell, 1972). This drug 
is mainly used combined with artesunate for the treatment of uncomplicated malaria. The 
treatment regime comprises a 3 day treatment course with a daily dose of 4 mg/kg/day 
artesunate and 25 mg/kg of mefloquine either split over 2 days as 15 mg/kg and 10 mg/kg or 
over 3 days as 8.3 mg/kg/day once a day for 3 days. It has been hypothesized that this drug 
acts through inhibiting the ingestion of host cell hemoglobin (WHO, 2010). It is used in 
prophylaxis, as well as, in the treatment of chloroquine resistant P.falciparum, and in 
combination with primaquine phosphate to treat uncomplicated P.vivax malaria 
(http://www.cdc.gov/malaria/pdf/treatmenttable.pdf, accessed 19 April 2010). This is one of 
the antimalarials with most common side effects, e.g., severe depression, anxiety, paranoia, 
aggression, nightmares, insomnia and seizures. It has also been reported to be associated with 
birth defects, among others (Alkadi, 2007).  
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Mefloquine is mainly metabolised by CYP3A4 to its two major inactive metabolites 
carboxymefloquine and hydroxymefloquine (Kerb et al., 2009). 
Extensive resistance has emerged in SE Asia (mainly Thailand) and in some other regions 
(e.g. Kenya). Due to its structural similarity with quinine, cross-resistance should be expected 
between the two drugs (Nelson et al., 2005). 
 
Lumefantrine 
Lumefantrine (Benflumetol) is a synthetic aryl amino alcohol quinoline originally synthesized 
by the academy of military medical sciences in Beijing, presently only available in the market 
as a co-formulation with artemeether, in tablets containing 20 mg of artemeether and 120 mg 
lumefantrine (Premji, 2009). This combination was licensed under the name Coartem
®
 for the 
developing world in 1999, by Novartis AG. It is mainly used in Africa to treat uncomplicated 
P. falciparum malaria, being presently the most prevalent first liner in the world. The present 
administration format comprised by 6 doses/3 days (1.7/12 mg/kg body weight of artemether 
and lumefantrine, respectively, per dose, given twice a day for 3 days,) is a well-tolerated and 
efficient treatment for uncomplicated malaria, even in regions with multi-drug resistance 
(Makanga et al., 2006). Taking in account its structural characteristics, this antimalarial 
probably has a similar mechanism of action as the other amino alcohol quinolines, mefloquine 
and halofantrine. 
In the human host this drug undergoes biotransformation mainly through CYP3A4, to form 
desbutyl-lumefantrine, which has a higher antiparasitic activity that the parent compound. 
This is the only lumefantrine metabolite characterized (Kerb et al., 2009). 
 
Halofantrine  
This drug represents another arylamino-alcohol quinoline, hence structurally related to 
mefloquine and lumefantrine. This compound was developed in parallel with mefloquine by 
the Walter Reed Army Institute of Research in collaboration with SmithKline Beecham in the 
late 1960s. The use of this antimalarial has been mostly discontinued, due to its short half life 
(1-2days), slow and variable absorption and – most importantly- severe side effects; of 
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particular concern is its cardiotoxicity (Kitchen et al., 2006). Together with mefloquine and 
lumefantrine, it is hypothesizes that this antimalarial acts by inhibiting the ingestion of host 
cell haemoglobin.  
Studied performed with this antimalarial in microsomes, indicated a major role of CYP3A4 
and to a minor extend CYP3A5 in the metabolism of halofantrine to N-debutylhalofantrine, its 
major metabolite (Baune et al., 1999). 
 
1.1.3.2. ANTIFOLATES  
This group of antimalarials targets the de novo antifolate synthesis pathway in the 
Plasmodium. The antifolates can be subdivided in two groups, the inhibitors of the 
dihydropteroate synthase (DHPS) (class I antifolates), and the inhibitors of the dihydrofolate 
reductase (DHFR) (class II antifolates) (Wang et al., 2004). Their structures are shown in 
figure 3. 
 
Dapsone 
Dapsone was synthesized for the first time in the early 20
th
 century, as the result of a search 
for molecules that produced azo dyes (Fromm and Wittmann, 1906). This drug has been  used 
as a monotherapy for malaria (P.falciparum and P.vivax)in some circumstances, but presently 
is only rarely used for prophylaxis in combination with other antimalarials, due to its limited 
efficacy and severe hemolytic side effects in individuals carrying G6PD mutations, quite 
common in Africa (Nzila, 2006). 
Dapsone is also used in the treatment of dermatological inflammatory diseases such as 
dermatitis herpetiformis and in human chemotherapy (Nzila, 2006). The toxicity of this 
compound is thought to be initiated by the formation of hydroxylamine metabolites trough the 
action of CYP2E1 (Mitra et al,. 1995).  
The inhibitors of dihydrofolate reductase (Type II antifolates), include a higher range of 
drugs, e.g., proguanil, chlorproguanil, pyrimethamine (Fig.3). 
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Proguanil 
The first described antifolate antimalarial drug was proguanil. As a number of other 
antimalarials, it was the result of an intensive effort by the British Imperial Chemical 
Industries, to synthesize new antimalarials during the Second World War. The first reports on 
this drug are from 1945, showing its activity against avian malaria. This drug has been used as 
a prophylactic agent, either as a monotherapy or in combinations with chloroquine or, more 
recently, with atovaquone. The potency of proguanil led to the search for further active 
analogues, leading to the discovery of chlorproguanil and clociguanil (Nzila, 2006). 
 
 
Figure 3: Chemical structures of the most commonly used type I (dapsone) and type II antifolates 
(proguanil, chlorproguanil and pyrimethamine). 
 
Chlorproguanil 
Chlorproguanil is generated by the chlorination of proguanil. This compound was initially 
recommended for prophylactic use, but due to inadequacy of the recommended dose, no 
prophylactic protection was acquired (Nzila, 2006).  
Dapsone 
Type I antifolates 
Proguanil Pyrimethamine Chlorproguanil 
Type II antifolates 
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Both proguanil and chlorproguanil are metabolised respectively to cycloguanil and 
chlorcycloguanil (the active metabolite), by CYP2C19 and to a lesser extent by CYP3A4. 
These enzymes are also involved in the inactivation of the parent compounds to 4-
chlorophenylbiguanide and dichlorophenylbiguanide (Kerb et al., 2009). 
 
Pyrimethamine 
The last member of the class II of antifolates is pyrimethamine, initially used in anti-cancer 
therapy. Due to its structural similarity to proguanil, its antimalarial activity was hypothesized 
and later confirmed (Falco et al., 1951).  This antimalarial used initially as a monotherapy is 
nowadays only administered in combination with sulfadoxine (section 1.1.3.2.1) (Nzila, 
2006). 
 
1.1.3.2.1. ANTIFOLATES COMBINATION THERAPY 
The combination between antifolates from class I and II is synergistic; hence they are 
normally used in combination for the treatment of malaria. The most widely used antifolate, 
pyrimethamine, is usually used in combination with sulfa drugs like sulfadoxine (Fansidar
®
), 
or with dapsone (Malprin
®
). The short half life of dapsone decreases significantly the 
synergistic effect of the combination, thereby decreasing dramatically its efficiency. The other 
combination, Fansidar
®
, has been widely used in malaria endemic regions, with a higher 
success rate than Malprin ® (Nzila, 2006).  
Another combination is proguanil/dapsone. This has been tested in treatment and prophylaxis 
of malaria. Recently, a new combination of these two drugs with artesunate has also been 
tested (Nzila, 2006). Both combinations are presently not widely used. 
Chlorproguanil, a derivative of proguanil, is also available in combination with atovaquone; 
this fixed-dose combination has been reporter as highly effective in P.falciparum malaria 
prophylaxis and treatment (Nicosia et al., 2008). 
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1.1.3.3. ARTEMISININ AND DERIVATIVES 
Artemisinin, the active principal of the Chinese medicinal herb Artemisia annua and its 
derivates (dihydroartemisinin, arteether, artemeether and artesunate) are the group of 
compounds with the highest parasite reduction ratio (~10000/ erythrocyte cycle) and low 
toxicity (White, 1997). They have the broadest parasite stage specificity, being effective in 
most intra-erythrocytic cycle stages, due to a pleiotropic action in the parasite believed to be 
associated to the collapse of the characteristic endoperoxide functional bridge and consequent 
generation of oxygen radicals (Ter Kuile et al., 2003; Skinner et al., 1996). The resulting 
alkylating molecules lead to the disruption of the parasite essential functions, enzymes and 
membrane integrity (Meshnick, 2002).  
Artemisinin is metabolized to four inactive compounds (deoxyartemisinin, 
deoxydihydroartemisinin, 9, 10-dihydrodeoxyartemisin and the so called “crystal 7”) due to 
the action of mainly CYP2B6, or in cases where the levels of CYP2B6 are low, by CYP3A4. 
The derivatives artesunate, artemeether and arteether are metabolized to the active compound 
dihydroartemisinin (DHA) by CYP2A6, CYP3A4/5 and CYP3A4 (with a minor contribution 
of CYP2B6 and CYP3A5), respectively (Kerb et al., 2009). 
With the rise and global spread of P. falciparum resistant to the mainstay antimalarials 
chloroquine and pyrimethamine, a new paradigm rose in the last ten years – the use of these 
well tolerated and highly efficacious antimalarials in combination strategies with long half life 
drugs. These combination therapies will be further discussed in the next chapter. 
(www.rollbackmalaria.org/cmc_upload/0/000/015/364/RBMInfosheet_9.htm, accessed 04 
February 2010). 
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Figure 4: Chemical structures of artemisinin and its derivatives. 
 
1.1.3.3.1. ARTEMISININ COMBINATION THERAPY (ACT)  
Although possessing the highest known antimalarial effect, the use of artemisinin and its 
derivatives as a monotherapy is usually associated with frequent recrudescence of the 
infection, mainly due to the extreme short half life of these compounds (Alin et al., 1995). To 
reduce recrudescence and prevent or slow the development of resistance, WHO has been 
recommending the use of artemisinin combined with another effective more slowly 
eliminated antimalarial (White, 1999). This strategy includes another important logistic point 
– the therapy can be completed in three days, not in the minimum of seven days postulated for 
artemisinin monotherapies. 
The rationale of this type of therapy is based on 4 characteristics: 1. The fast acting 
artemisinin will reduce dramatically the parasite load in the first hours of treatment; 2. The 
slowly eliminated combination partner will only face a decreased amount of parasites; 3. 
Since the mechanism of action of both combination partners is different, the slowly 
eliminated partner, will target the parasites that might have been selected by the artemisinin 
partner; 4. These drugs frequently show a pharmacodynamic synergism between the 
Artemisinin 
Artesunate Artemether Arteether Dihydroartemisinin 
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combination partners, being another advantage of this type of drugs (Mariga et al., 2005; Gil 
and Gil Berlung, 2007). 
The currently deployed ACTs include: artemether-lumefantrine (Coartem
®
, Novartis, Basel), 
artesunate-amodiaquine (Coarsucam
®
 or Northeorp
®
, Sanofi-Aventis, Paris) artesunate-
mefloquine, artesunate-sulfadoxine-pyrimethamine and DHA-piperaquine (WHO, 2009). As 
with most co-administrations, these combination therapy strategies, although effective, also 
increase the possibility of drug-drug interaction. Little is known about these potential 
interactions.  
 
1.1.3.4. NAPTHOQUINONES 
Atovaquone 
Atovaquone is a 2-hydroxinaphtoquinone (Fig. 5), indentified in the 1940s, but only certified 
as an antimalarial in 1997 in combination with proguanil, available under the commercial 
name Malarone
®
. This compound is as an analogue of coenzyme Q (ubiquinone), acting by 
interfering with the organelle membrane potential of the malaria parasite. Drug resistance to 
this compound appeared very rapidly upon its implementation as a monotherapy; however, its 
combination with proguanil retarded this resistance. This combination has been implemented 
as prophylaxis for travelers to South East Asia (Hyde, 2007).  
 
Figure 5: Chemical structure of atovaquone. 
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1.2. DRUG METABOLISM 
The majority of the xenobiotics that enter the body undergo several biotransformations, in 
order to be transformed from a lipophilic compound to a more hydrophilic compound, easily 
excreted, to the bile or urine. Therapeutic drugs correspond to one of the most important 
xenobiotic exposures in the modern times being the main general focus of this thesis. 
Drug metabolism occurs mainly in the liver, but tissues like the gastrointestinal tract, kidneys, 
skin and lungs may also be involved in this process. This process starts with the entry of the 
drug in the cells that may happen by diffusion or by the action of specific uptake transporters 
(phase 0), followed by two independent phases: Phase I, or functionalization process, involves 
reactions of hydrolysis, reduction and oxidation; Phase II, or conjugation phase, involves 
conjugation of the drug molecule with a hydrophilic endogenous substrate. As a general 
concept, phase I precedes phase II, but this is not strict, as they may occur independently from 
each other. The biotransformation process will end with the transport of the hydrophilic 
compounds to the outside of the cell (phase III), also this transport phase may occur 
independently of the previously described metabolic phases.   
 
1.2.1. PHASE I 
In this first stage of drug metabolism, the enzymes involved are mainly from the cytochrome 
P450 family (CYP) and to a certain extent flavin monooxigenases. The P450’s and flavin 
moonoxigenases are both anchored in the membrane of the endoplasmatic reticulum of the 
cells. The similarity between these enzymes is reflected by on their main chemical reaction, as 
they both use NADPH + oxygen to oxidize their substrates (Kenakin, 2009).  
 
1.2.1.1. CYTOCHROME P450S 
The first descriptions of cytochrome P450s occurred in the 1950s; First by Axelrod and 
Brodie et al., who identified an enzymatic system in the endoplasmic reticulum, which was 
able to oxidize xenobiotics (Axelrod, 1955; Brodie et al., 1955). Later in the same decade 
Garfinkel and Klingenberg detected a carbon monoxide binding pigment with an absorption 
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maximum at 450nm (Garfinkel, 1958; Klingenberg 1958). This was demonstrated to be a 
hemoprotein of the b-type class in 1964 by Omura and Sato, and named cytochrome P450 due 
to its characteristic absorption at 450nm (Omura and Sato, 1964 a and b). At this time it was 
thought only one cytochrome P450 existed; further studies identified the different enzymes 
that belong to this family (reviewed in Josephy, 1997). 
Due to the large number of human P450s, a specific nomenclature had to be established, 
essentially based in the degree of homology between the proteins amino acid sequence. 
Enzymes sharing ≥ 40% a.a. identity are classified in the same family. To share the same 
subfamily the enzymes have to share ≥ 55% a.a. identity. The first Arabic number indicates 
the family (CYP3), the letter indicates the subfamily (CYP3A) and another Arabic number 
corresponds to the individual gene (CYP3A4). The gene name is written in italic (CYP3A4) 
and the mRNA and protein in regular capital letters (CYP3A4). Taken this classification in 
consideration, presently, the 57 human P450s are organized in 18 families and 44 subfamilies 
(Nelson, 1999; http://drnelson.uthsc.edu/CytochromeP450.html, accessed 17 April 2010). 
The major human CYP enzymes responsible for catalyzing drug biotransformation are 
members of families CYP1, CYP2 and CYP3. Taken together these 3 families are responsible 
for ~80% of the metabolism of clinical used drugs (Bertz and Granneman, 1997). The 
principal isoforms involved in drug metabolism include CYP1A2, 2A6, 2B6, 2C8, 2C9, 
2C19, 2D6, 2E1 and 3A4/5 (Figure 6). 
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Figure 6: Relative contribution of cytochrome P450s to the metabolism of the 200 most commonly 
prescribed drugs in the USA, compiled from Zanger et al., 2008. 
The P450s of families 4-51 are involved in endogenous metabolic pathways of steroids, fatty 
acids, prostaglandins, etc. (Zanger et al., 2008). 
The enzymatic activity of the P450s may be influenced by several factors, both genetic, e.g., 
genetic variability and gene regulation and non-genetic, i.e., age, gender, hormonal status and 
disease. Of importance for this project is the variability of P450s due to the regulation of gene 
transcription, especially by nuclear receptors. This will be further discussed in chapter 1.2.4. 
 
1.2.2. PHASE II 
Phase II reactions are conjugation reactions, mainly, glucuronidations, sulfonations, 
methylations, acetylations. These reactions covalently link a functional group onto the target 
molecule to create highly polar, water soluble, metabolites that are rapidly excreted into urine 
(Kenakin, 2009). As stated, frequently the molecule has been previously modified through 
hydroxylation creating chemically favorable groups for the conjugation reactions.  The major 
enzymes in phase II are the UDP glucuronosyltransferase (UGT), sulfotransferases (SULT), 
arylamine N-acetyltransferases (NAT), glutathione S-transferases (GST), thiopurine S-
methyltransferases (TPMT) or the catecholamine-O-methyltransferases (COMT). 
 
1.2.4. NUCLEAR RECEPTOR MEDIATED GENE REGULATION IN DRUG 
METABOLISM 
Variations in the activity of DMEs can lead to altered drug levels, and consequently, to a 
modulation of its pharmacodynamics and risk of side effects.  
The control of the expression of DME´s may occur at four different stages: Transcription, 
mRNA stability, translation and in a post-translational way. On the transcriptional level, these 
enzymes are controlled mainly by transcription factors. Of particular interest for this thesis is 
the gene expression control by a particular family of ligand-dependent transcriptions factors, 
the nuclear receptors.  
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The first nuclear receptor was identified in the 1960s by Jensen and collaborators, their work 
identified estradiol cellular activity as being mediated by a specific high-affinity receptor 
(Jensen, 1962). Since then nuclear receptors have been discovered and organized as part of a 
family comprising, 48 members in humans (table 1), that are responsible for sensing the 
presence of many different small molecules, including endobiotics and xenobiotics. In 
response to it, NRs interact with other proteins to regulate the expression of their respective 
target genes, controlling development, homeostasis and metabolism processes in the organism 
(Gronemeyer et al., 2004).  
 
Table 1: The human nuclear receptor family according to its official nomenclature and examples of 
ligands (adapted from Germain et al., 2006 and Moore et al., 2006). 
Official 
Nomenclature 
Name Abbreviation Ligand 
NR1A1 Thyroid hormone receptor alpha TRα Thyroid hormones 
NR1A2 Thyroid hormone receptor beta TRβ Thyroid hormones 
NR1B1 Retinoic acid receptor alpha RARα Retinoic acid 
NR1B2 Retinoic acid receptor beta RARβ Retinoic acid 
NR1B3 Retinoic acid receptor gamma RARγ Retinoic acid 
NR1C1 Peroxisome proliferator- activated receptor alpha PPARα Fatty acids 
NR1C2 Peroxisome proliferator- activated receptor delta PPARδ Fatty acids 
NR1C3 Peroxisome proliferator- activated receptor 
gamma 
PPARγ Fatty acids 
NR1D1 Reverse erb alpha Rev-erbα Unknown 
NR1D2 Reverse erb beta Rev-erbβ Unknown 
NR1F1 RAR-related orphan receptor alpha RORα Cholesterol 
NR1F2 RAR-related orphan receptor beta RORβ Retinoic acid 
NR1F3 RAR-related orphan receptor gamma RORγ Unknown 
NR1H2 Liver X receptor alpha LXRα Oxysterols 
NR1H3 Liver X receptor beta LXRβ Oxysterols 
NR1H4 Farnesoid X receptor FXR Bile acids 
NR1I1 Vitamin D receptor VDR Vitamin D 
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NR1I2 Pregnane X receptor PXR Xenobiotics 
NR1I3 Constitutive androstane receptor CAR Xenobiotics 
NR2A1 Hepatocyte nuclear factor 4 alpha HNF4α Linoleic acid 
NR2A2 Hepatocyte nuclear factor 4 gamma HNF4γ Unknown 
NR2B1 Retinoid X receptor alpha RXRα Retinoic acid 
NR2B2 Retinoid X receptor beta RXRβ Retinoic acid 
NR2B3 Retinoid X receptor gamma RXRγ Retinoic acid 
NR2C1 Testis receptor 2 TR2 Unknown 
NR2C2 Testis receptor 4 TR4 Unknown 
NR2E1 Tailless-like receptor TLX (TLL) Unknown 
NR2E3 Photoreceptor-specific nuclear receptor PNR Unknown 
NR2F1 Chicken ovalbumin upstream promoter– 
transcription factor I 
COUP-TFI Unknown 
NR2F2 Chicken ovalbumin upstream promoter– 
transcription factor II 
COUP-TFII Unknown 
NR2F6 Chicken ovalbumin upstream promoter– 
transcription factor III 
COUP-TFIII 
(EAR2) 
Unknown 
NR3A1 Estrogen receptor alpha ERα Estradiol, 
Estrogens 
NR3A2 Estrogen receptor beta ERβ Estradiol, 
Estrogens 
NR3B1 Estrogen-receptor-related receptor alpha ERRα Unknown 
NR3B2 Estrogen-receptor-related receptor beta ERRβ DES 
NR3B3 Estrogen-receptor-related receptor gamma ERRγ DES 
NR3C1 Glucocorticoid receptor GR Cortisol 
NR3C2 Mineralocorticoid receptor MR Aldosterone 
NR3C3 Progesterone receptor PR Progesterone 
NR3C4 Androgen receptor AR Testosterone 
NR4A1 NGF-induced factor B NGFI-B Unknown 
NR4A2 Nur-related factor 1 NURR1 Unknown 
NR4A3 Neuron-derived orphan receptor 1 NOR1 Unknown 
NR5A1 Steroidogenic factor 1 SF1 Unknown 
NR5A2 Liver receptor homologous LRH-1 Unknown 
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NR6A1 Germ cell nuclear factor GCNF Unknown 
NR0B1 DSS-AHC critical region on the chromossome 
gene 1 
DAX-1 Unknown 
NR0B2 Small heterodimer partner SHP Unknown 
 
The NR family can be divided in 3 distinct groups according to the nuclear receptor ligand 
specificity: (a) the endocrine receptors (e.g., androgen receptor, estrogen receptor and 
glucocorticoid receptor), that respond to steroid hormones; (b) the so-called orphan receptors, 
which are proteins with all the structural characteristics of a nuclear receptor, but with no 
ligand yet identified; (c) a last group, growing from the previous one representing  the 
adopted orphan receptors, which had their ligands identified since their own isolation (e.g. 
pregnane X receptor, constitutive androstane receptor) (Sonada et al., 2008).  
 Some of these nuclear receptors may act as a monomer, but the majority acts as dimers, 
either with themselves (homodimer) or with the nuclear receptor RXR (RXR-heterodimer) 
(Olefsky, 2001).  
Although with different ligand specificities, the structure of the nuclear receptors is very 
similar throughout the family. It comprises 5 distinct domains: an N-terminal domain, a DNA 
binding domain (DBD), a hinge region, a ligand binding domain (LBD) and a C-terminal 
domain. (Fig.7) (Giguère, 1999). 
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Figure 7: Structural organization of nuclear receptors. 
(http://upload.wikimedia.org/wikipedia/commons/3/3e/Nuclear_Receptor_Structure.png, accessed on 21 April 
2010) 
The main areas responsible for the specific features of the nuclear receptors are the amino 
terminus, the LBD and the DBD.  The amino terminus contains a transactivation domain (AF-
1) that is recognized by co activators and/or other transcription factors. The LBD identifies 
specific ligands and directs the biologic response to this stimulus. The DBD is responsible for 
the binding of the nuclear receptor to specific binding sites in the promoter regions of the 
target genes. These binding sites or response elements are derived from the consensus motif, 
RGGTCA. The modification, extension or duplication (these duplications may have alternate 
relative orientations, e.g. direct, inverted or everted) of this sequence, creates response 
elements that more or less selective for a particular nuclear receptor (Gronemeyer et al., 
2004). 
Several of these nuclear receptors exhibit specific xenobiotic binding capacity. These, so 
called, xenosensors are capable of regulating the transcriptional activation of several genes 
encoding for phase I and II drug-metabolizing enzymes, as well as transporters. The major 
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xenobiotic receptors, pregnane X receptor (PXR) and constitutive androstane receptor (CAR), 
will be further discussed in the next chapters. 
 
1.2.4.1. PREGNANE X RECEPTOR (NR1I2; PXR) 
The pregnane X receptor was initially identified in 1998, as being a nuclear receptor involved 
in the induction of cytochrome P450s, particularly CYP3As, and was named PAR, SXR and 
PXR in the respective publications (Bertilsson et al., 1998; Blumberg et al., 1998; Kliewer et 
al., 1998). Further investigations identified this nuclear receptor as regulator of other key 
DMEs and transporter, such as, CYP1A1, 1A2, 2A6, 2B6, 2C8, 3A4, 3A5, GSTs, UGTs, 
SULTs, MDR1 and MRP2 (Maglich et al., 2002; reviewed in Tirona and Kim, 2005). This 
nuclear receptor acts as a heterodimer together with RXRα, binding to response elements such 
as DR3, DR4, DR5, ER6, ER8 and IR0 in the promoter regions of the aforementioned genes 
(Lehmann et al., 1998; Geick et al., 2001; Goodwin et al., 1999 and 2001; Kast et al., 2002; 
Sonoda et al., 2002) 
PXR is mainly expressed in the liver, and represents one of the most promiscuous receptors, 
being activated by a large range of structurally diverse compounds, including xenobiotics and 
endobiotics. This is due to a ligand-binding pocket unusually large (reaching >1100 Å3) and 
flexible, spherical in shape and extremely hydrophobic, as twenty of the twenty eight residues 
in the ligand-biding pocket are hydrophobic (Watkins et al., 2001). A representative list of 
PXR ligands is described in table 2 (Orans et al., 2005; Carnahan and Redinbo, 2005). 
Of central interest for this thesis is the previously described role of artemisinin, arteether and 
artemeether as ligands of PXR (Burk et al., 2005). These data led to the follow up project 
described in this thesis, with the intent of identifying new ligands among the other 
antimalarials available on the market. 
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Table 2: List of some known agonists of PXR (for a more comprehensive review on PXR ligands, Meyer zu 
Schwabedissen and Kim, 2009). 
PXR Agonists 
Artemisinin Docetaxel Nifedipine 
Arteether Efavirenz Paclitaxel 
Artemether Fluvastatin Tamoxifen 
Atorvastatin Ginko Biloba extract Lithocolic acid 
BK8644 Hyperforin 5 -pregnane-3, 20-dione 
Carbamazepin Ifosfamide Progesterone 
Clotrimazole lovastatin Ursodeoxycholic acid 
 
 
1.2.4.1.1. PXR GENETIC STRUCTURE AND VARIABILITY  
The human PXR gene was mapped to chromosome 3 (3q12-q13.3) and spans approximately 
35kb. It consists of 9 exons, with the translation starting site located in exon 2 (Fig 8). The 
open reading frame (ORF) codes for a 434 amino acids protein (49.7kDa), named hPXR.1, 
representing the main splice variant of PXR (Sandanaraj et al., 2008).  
Nine other splice variants have been identified for this protein (Lamba et al., 2004; Kurose et 
al., 2005). The second most common transcript variant is hPXR.2, encoding a 393 a.a. protein 
lacking 41 a.a. from the ligand binding domain (Sandanaraj et al., 2008). Another interesting 
splice variant is PAR2, it difers from PXR, by being transcribed from exon 1b, while PXR is 
trancribed from exon1a. PXR has a CTG translation start site in exon 2, whereas PAR2 has an 
ATG translation start site in exon 1b leading to an additional 39 amino acids at the amino 
terminal end (Lamba et al., 2008). 
The first polymorphisms in the coding and non-coding regions of the human PXR gene were 
described in 2001. These were associated with individual phenotype variations in basal and 
rifampicin inducible expression of CYP3A and MDR1/P-gp (Zhang et al., 2001; Hustert et 
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al., 2001). Meanwhile, a large number of SNPs have been described in this gene, also leading 
to altered induction of target genes. They may affect the disposition of many currently 
administrated drugs, metabolised and/or transported by PXR induced proteins. Ultimately, 
polymorphisms in PXR leading to functional changes in this receptor may play a key role in the 
regulation of drug response. For a comprehensive review of the previously identified 
polymorphisms in PXR please refer to the table in annex1 and figure 8. 
 
Figure 8: Genomic structure of the PXR gene and protein. In the gene structure the main coding region 
single nucleotide polymorphisms are annotated (Cavaco, 2008). 
 
 
 
1.2.4.2. CONSTITUTIVE ANDROSTANE RECEPTOR (NR1I2; CAR)  
Human constitutive androstane receptor (hCAR), was initially cloned by Baes and colleagues 
in 1994, and named MB67 (Baes et al., 1994). As PXR, it functions as a xenosensor, sensing 
the presence of xenobiotics and in response, upregulating the expression of key DMEs, e.g., 
CYP1A, SULT1A1, FMO5, CYP2B, CYP3A, CYP2C, CYP2A, UGT1A1, GSTA1, ALDH1A, 
MRP3, MDR1, through the binding to DR1, DR3, DR4, DR5, ER6, and ER8 binding sites in 
their regulatory regions (Li and Wang 2010). The similarities between these two nuclear 
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receptors are visible also, when it concerns their heterodimerization partner, both form  
heterodimers with RXRα (di Masi et al. 2009). 
CAR received its name constitutive androstane/activated receptor due to its particular 
characteristic of being constitutively active in immortalized cells but not in the liver in the 
absence of ligand. This led to its initial definition as a constitutive active receptor (Choi et al 
1997).  Besides highly expressed in the liver, CAR is also expressed in the intestine, and to a 
minor extent in human heart, skeletal muscle, brain, kidney, and lung (Baes et al., 1994; Wei et 
al., 2002; Arnold et al., 2004) 
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1.3. AIMS  
This project was motivated by the fact that only limited data was available concerning 
antimalarial chemotherapy and modulation of the PXR/CAR system. Induction of PXR- 
and/or CAR-dependent drug metabolism and transport by antimalarial drugs may result in 
autoinduction of metabolism and drug-drug interactions, compromising the success of 
antimalarial therapy. This is of particular relevance when taking in account the global 
importance of malaria as a major lethal infectious disease and facing the increasing need of 
antimalarial combination therapies 
In the first part of this project we intended to elucidate the capacity of the currently used 
antimalarial drugs and their main metabolites to activate PXR and/or CAR, and to evaluate 
the drug-drug interaction potential of the antimalarials, using in vivo and in vitro assays. 
In the second sub-project we intended to understand the genetical basis of variable PXR-
dependent induction of key cytochrome P450s, through a molecular epidemiology approach 
using previously studied healthy individuals exposed to pivotal artemisinin derivatives as case 
studies.  
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2. MATERIAL AND METHODS 
 
2.1. MATERIAL 
 
2.1.1. ANTIMALARIC DRUGS AND METABOLITES 
 
2.1.1.1. SELECTION OF THE COMPOUNDS TO BE TESTED 
The compounds tested in this project were selected based on malaria treatment 
recommendations. If known and available, their major active and non-active metabolites were 
also included in this study. The selected compounds were used in sub-project 1 and are 
described in table 3. 
 
2.1.1.2. CHARACTERISTICS OF ANTIMALARIC DRUGS AND THEIR 
METABOLITES 
For the study of the induction capacity of the antimalarials and metabolites, stock solutions of 
100mM of the compounds were prepared in Me2SO. This solvent was used as a control in all 
induction assays. 
 The molecular weight and supplier of each compound is described in table 3. 
Chlorocycloguanile, pyrimethamine and sulfadoxine were kindly provided by Dr. José Pedro 
Gil, Department of medicine, Karolinska Institutet, Stockholm, Sweden. 
Table 3: List of compounds tested in sub-project 1. For each compound molecular weight and supplier are 
given. 
Name Molecular Weight Supplier 
Amodiaquine 464.8 Sigma 
Arteether 312.4 Dafra 
Artemether 298.4 Dafra 
Artemisinin 282.3 Dafra 
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Artesunate 384.4 Dafra 
Atovaquone, free base 366.8 GlaxoSmithKline 
Carboxymefloquine 309.16 TRC 
Chlorocycloguanile HCl 251.7 - 
Chloroquine 515.0 Sigma 
Cycloguanile HCl 288.2 TRC 
Dantrolene sodium salt 336.2 Sigma 
Dapsone (4-aminophenyl sulfone) 248.3 TRC 
Dapsone Hydroxylamine 264.3 TRC 
Deoxy-arteether 296.4 TRC 
Deoxy-artemisinin 266.3 TRC 
Desbutyl-benflumetol 472.8 Novartis 
Desethylchloroquine 291.8 TRC 
Didesethylchloroquine 263.8 TRC 
Halofantrine 536.9 Sigma 
Isoquinine 324.4 TRC 
Lumefantrine 530.0 Novartis 
Mefloquine HCl 414.8 Sigma 
N-desethylamodiaquine (DEAQ) 327.8 TRC 
Primaquine 455.3 Sigma 
Proguanile HCl 290.2 GlaxoSmithKline 
Pyrimethamine 248.7 - 
Pyronaridine 910.0 Avachem 
Quinine 324.4 Sigma 
Sulfadoxine 310.3 - 
 
 
2.1.2. COMMON REAGENTS 
 
Common reagents used in this project were obtained from the following companies: GE 
Healthcare (Freiburg, DE), Biozym (Hess. Oldenburg, DE), Difco (Detroit, MI, USA), Fluka 
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(Buchs, CH), Invitrogen (Groningen, NL), Merck (Darmstadt, DE), Roth (Karlsruhe, DE), Serva 
(Heidelberg, DE) and Sigma (Deisenhofen, DE). 
 
2.1.3. ENZYMES AND PCR REAGENTS 
Enzymes were obtained from the following companies, and used together with specific 
buffers as described by the supplier: GoTaq  Polymerase (Promega, Fitchburg, WI, USA). 
Reagents used for PCR reactions were obtained from the following companies: dNTPS 
(Promega, Fitchburg, WI, USA), Real time qPCR master mix (Eurogentec, Seraing, BE). 
 
2.1.4. KITS 
Kits were used according the manufacturer instructions and were obtained from the following 
companies: PureYield™ Plasmid Midiprep System (Promega, Fitchburg, WI, USA); 
Effectene Transfection Reagent (Qiagen, Hilden, DE); mirVana Kit (Applied 
Biosystems/Ambion, Austin, USA); Illustra GenomiPhi V2 DNA Amplification Kit (GE 
Healthcare, Little Chalfont, Buckinghamshire,UK)  PureYield
TM 
Plasmid Midiprep System 
(Promega, Fitchburg, WI, USA). 
 
2.1.5. CELL LINES, CELL CULTURE MEDIUMS AND SUPPLEMENTS  
COS1: African green monkey kidney fibroblast-like cell line (American type culture 
collection, Manassas USA). 
HeLa: Human cervical carcinoma cell line (American type culture collection, Manassas 
USA). 
All cell culture media, supplements and fetal calf serum were obtained from Invitrogen 
(Groningen, NL). 
Two additional compounds were used as controls in the mammalian two hybrid and gene 
reporter assays, namely, 6-(4-chlorophenyl)imidazo [2,1-b]thiazole-5-carbaldehyde O-(3,4-
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dichlorobenzyl)oxime (CITCO)  obtained from Biomol (Plymouth, PA), and Rifampicin 
(Sigma, Deisenhofen, DE)). 
 
2.1.6. PLASMIDS 
Specific plasmids were used for the mammalian two hybrids gene reporter assay and 
C.A.R.L.A. Their characteristics and origin are described in table 4.  
 
Table 4: Plasmids used in the mammalian two hybrid assay, reporter gene assay and C.A.R.L.A. 
Name Description Reference 
pGL3-G5 Luciferase reporter plasmid used in mammalian two 
hybrid assays 
Arnold et al., 2004 
pCMVß ß-Galactosidase expression vector Clontech 
pUC18 Fill up plasmid for transfections Invitrogen 
pM-DRIP 
205 
(527-774) 
Expression plasmid of the fusion protein GAL4-
DBD/DRIP205-RID (a.a.527-774) 
Arnold et al.,2004 
pVP16-
CARSV2 
(105-353) 
Expression plasmid of the fusion protein VP16-
AD/CARSV2-LBD (a.a.105-353) 
Arnold et al.,2004 
pM-SRC1 
(583-783) 
Expression plasmid of the fusion protein GAL4-
DBD/SRC1-RID (a.a.583-783) 
Arnold et al.,2004 
pVP16-PXR 
(108-434) 
Expression plasmid of the fusion protein VP16-
AD/PXR-LBD (a.a.108-434) 
Burk et al., 2005 
pGL3-
CYP3A4 
CYP3A4 luciferase promoter reporter construct Hustert et al., 2001 
pcDhuPXR Expression plasmid of human PXR Geick et al ,2001 
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2.1.7. OLIGONUCLEOTIDES 
The oligonucleotides used during this project are described in tables 5 and 6. For the re-
sequencing of PXR specific primers had to be designed and amplification conditions had to be 
optimized.   
 
Table 5: Oligonucleotides used for quantitative real time RT (reverse transcription)-PCR. The primers 
were obtained from Biomers (Ulm, Germany), and dissolved to a final concentration of 100µM according to the 
indications from the supplier. Probes were obtained from Applied Biosystems (Applied Biosystems, Foster City, 
CA, USA). 
Gene Oligonucleotide Sequence (5’-3’) Label Assay 
conditions 
(nM) 
Reference 
1
8
S
 
Fw Primer ACCGCAGCTAGGAATAATGGA  400  
Rv Primer GCCTCAGTTCCGAAAACCA  400 
Probe ACCGCGGTTCTATTT 5’VIC/3’
MGB/NF
Q 
200 
C
Y
P
3
A
4
 
Fw Primer TGTCCTACCATAAGGGCTTTTGTAT  400 Wolbold et al., 
2003 
Rv Primer TTCACTAGCACTGTTTTGATCATGTC  400 
Probe CTTTTATGATGGTCAACAGCCTGTGCTG 5’FAM/3
’TAMR
A 
200 
C
Y
P
2
B
6
 
Fw Primer GCTGAACTTGTTCTACCAGACTTTTTC  400 Burk et al., 
2005 
Rv Primer GAAAGTATTTCAAGAAGCCAGAGAAG
AG 
 400 
Probe TGTATTCGGCCAGCTGT 5’FAM/ 
3’MGB/
NFQ 
400 
M
D
R
1
 
Fw Primer CTGGTGTTTGGAGAAATGACAGATA  900 Burk et al., 
2005 
Rv Primer TGGTCATGTCTTCCTCCAGATTC  900 
Probe TCAAACATCACTAATAGAAG 5’FAM/ 
3’MGB/
NFQ 
240 
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Table 6: Primers, annealing temperatures and fragment sizes used for the re-sequencing of PXR. Primers 
where dissolved to a concentration of 100µM with water according with the information of the supplier (Thermo 
Fischer Scientific, Ulm, Germany). The primers used for sequencing are highlighted in bold.   
Name Sequence (5’-3’) T (oC) Fragment 
size (bp) 
Reference 
Promoter1Fw CCCAGCAGTGAGCTGTGTAA 56 644 Zhang et al. 2001 
Promoter1 Rv AGCTGAGGGCTCTTTCCTCT Zhang et al. 2001 
Promoter2Fw GCACCTGCTGCTAGGGAATA 56 568 Zhang et al. 2001 
Promoter2 Rv CCCCTCCTAAGTCCCAAGTC Newly designed 
Exon1a Fw TCAAGTGCTGGACTTGGGAC 69 460 Hustert et al. 2001 
Exon1a Rv CCCACTATGATGCTGACCTC Hustert et al. 2001 
Exon1b Fw TGCTCTCTGGTCCTGCACTA 56 411 Newly designed 
Exon1b Rv CCACATGCAGGCAAGACTC Hustert et al. 2001 
Exon2 Fw CTGAGGCCTCTACACATC 64 487 Hustert et al. 2001 
Exon2 Rv GAAGGAGACCTTTCCTGGGT Newly designed 
Exon3 Fw CTGGGACGCAAAGGCTAGTG 64 417 Hustert et al. 2001 
Exon3 Rv CCTGTTGCACACGGACAC Hustert et al. 2001 
Exon4 Fw TAACGGCTTCTGCTGCCTTG 64 367 Newly designed 
Exon4 Rv ATCCTTGGGGAACCTCAGTT Newly designed 
Exon5 Fw GCTGTGTGTGTATATGTGTGAGGA 60 566 Ferreira et al. 2008 
Exon5 Rv TTGGTGTCAGAAGACCCTCC Ferreira et al. 2008 
Exon6/7 Fw GAGATGAGAGGCAGCCAGAC 56 695 Newly designed 
Exon6/7 Rv GACTGGGACCTTCCCTGG Hustert et al. 2001 
Exon8 Fw TATGGCCTTGCTCCTCATTC 56 505 Newly designed 
Exon8 Rv CCCCTGTTTGCTTGTGTTTT Newly designed 
Exon9(1) Fw AATCTTTTCTCTGGCTGGCA 56 770 Newly designed 
Exon9(1) Rv TGTCAGAAGCTTGGCATGAC Newly designed 
Exon9 (2)Fw CAAATGTCAGAAGCTTGGCA 56 754 Newly designed 
Exon9(2) Rv TATTTCCACACCCCCACATT Newly designed 
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2.1.8. SOFTWARE 
Statistical analysis was performed using GraphPad Prism v.4 (GraphPad Software, San Diego, 
USA). Primer design was performed using Primer Blast in NCBI Homepage. Sequence 
alignment and new SNP search was performed using Geneious Pro V.4.8. 
 
2.1.9. HUMAN SAMPLES 
The human hepatocytes used in subproject 1 were kindly provided by Dr. Andreas Nüssler 
from Charité, Humbold University, Berlin. These hepatocytes were obtained from liver 
resections of patients with primary or secondary liver tumors. The harvesting and following 
procedures were done according to the institutional guidelines of the Charité, and with the 
written informed consent of each patient. The hepatocytes were isolated from the liver tissue 
and cultivated as reported elsewhere (Yuan et al., 2004).  
For subproject 2 a group of 75 healthy Vietnamese volunteers, described previously by 
Asimus et al 2007, were used in the study. The group comprises 72 subjects from the 
predominant Kinh ethnic group and 3 from Thai ethnicity.The participants were all judged to 
be healthy on the basis of medical history, physical examination and routine clinical 
laboratory determinations. Subjects who had taken any antimalarial drug within 1 month or 
any other drug within 2 weeks before the start of the study and those with a history of alcohol 
abuse were excluded from the study. Oral contraceptive use was not recorded. Thirty-six of 
the subjects were smokers of no more than 10 cigarettes per day.  
All participants provided written informed consent prior to enrolment. Study protocols were 
approved by the Ministry of Health, Hanoi, Vietnam, the Swedish Medical Products Agency, 
Uppsala, Sweden and the Ethics Committee of University of Gothenburg, Göteborg, Sweden. 
The studies were performed according to the principles of the Declaration of Helsinki. 
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2.2. METHODS 
2.2.1. PLASMID PREPARATION 
2.2.1.1. CHEMICALLY COMPETENT BACTERIAL CELLS  
TOP 10 F’ E.coli bacteria were transferred into 6ml of Ψ-broth medium and grown at 37°C up 
to an optical density at 550nm (OD550) of 0.3. One hundred ml of pre-warmed Ψ-broth 
medium was then inoculated with 5 ml of this pre-culture, and incubated up to an OD550 of 
0.45-0,5. This culture was then incubated on ice for 10 min and centrifuged at 3000 g, 5 min 
at 4°C. The pellet was ressuspended in 20ml ice-cold TfB I buffer, filled up to 60 ml and 
incubated on ice for 2h. This suspension was then centrifuged at 3000 g, 5min, 4°C. The 
pellet was ressuspended in 4ml of ice-old TfB II buffer and further incubated on ice for 15 
min. The bacteria were aliquoted and stored at -80°C until usage. 
Ψ-Broth-Medium: 2% Bacto-Trypton; 10 mM KCl; 0.5% yeast extract; autoclave; at the end add 0.2% 
MgSO4∙7 H2O; adjust pH with KOH to 7.6 
 TfB I buffer: 100 mM RbCl2; 50 mM MnCl2; 30 mM K-acetate; 10 mM CaCl2; 15% (v/v) glycerin; adjust pH 
with 0.2 M acetic acid to 5.8  
TfB II buffer: 10 mM MOPS, pH 7.0; 10 mM RbCl2; 75 mM CaCl2; 15% (v/v) glycerine 
 
2.2.1.2. BACTERIAL CELL TRANSFORMATION WITH PLASMID DNA 
One µL of plasmid DNA (100-500ng) was incubated with 50µL of pre-aliquoted TOP 10F’ 
competent cells on ice for 30 min, followed by a incubation at 42°C for 35 sec and a final 
incubation on ice for 2 min. 250 μl SOC media were added and the cells were incubated at 
37°C with shaking for 1 h. The bacteria were then spread on a LB agar plate containing 
ampicillin (0.2mg/ml), or directly inoculated in 50 ml of LB medium containing ampicillin 
and incubated over-night at 37°C. The purification of the plasmid was performed in the 
following day. 
SOC medium: 2% Bacto-Trypton; 0.5% yeast extract; 0.06% NaCl; 2.5 mM KCl; autoclave; + 2 mM MgCl2  
LB- (“Luria-Bertani”) medium: 2% Bacto-Trypton; 1% NaCl; 0.5% yeast extract;  
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LB agar plates: LB-medium with 1.5% Bacto-Agar; autoclave, and divide by the plates. 
 
2.2.1.3. ISOLATION OF PLASMID DNA 
The cells from an overnight culture were harvested by centrifugation and plasmid isolation 
was performed using the PureYield
TM 
Plasmid Midiprep System. This system uses silica-
membrane columns for a rapid and efficient extraction of high quality DNA for use in 
eukaryotic transfections and in vitro expression experiments. 
The extractions were performed according to the manufacturer’s instructions.  
 
2.2.1.4. QUANTIFICATION AND CONFIRMATION OF THE IDENTITY OF 
THE PLASMID DNA  
The plasmid DNA was quantified using a microvolume spectrophotometer. After assessing 
the DNA amount, this was diluted to a final concentration of 0.2µg/µL. 
0.5µg of plasmid DNA was digested with appropriate restriction endonucleases to confirm its 
identity by analysis of its restriction pattern. DNA digestions were carried out according to 
the manufacturer’s instructions. The digested DNA was analyzed by agarose gel 
electrophoresis. 
 
2.2.2. BASIC CELL CULTURE PROTOCOL 
For gene reporter and mammalian two hybrid assays, immortalized cell lines were used, 
specifically COS1 and HeLa. 
These cells lines were cultured in DMEM medium, supplemented with 10% FBS, 2mM L-
glutamine and 1% of penicillin/streptomycin. Twice a week they were subcultured in a ratio 
of 1:10. 
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2.2.3. TRANSIENT TRANSFECTION USING EFFECTENE® 
Effectene
®
 is a non-liposomal lipid formulation transfection reagent optimized to achieve 
high transfection efficiencies. This is achieved by an initial step of DNA condensation by 
interaction with the Enhancer
®
 followed by the addition of the Effectene and formation of 
condensed Effectene-DNA complexes. The Effectene forms micelles with uniform size, 
significantly independent of batch variation, ensuring high reproducibility of DNA 
transfection. 
Twenty hours before transfection COS1 and HeLa cells were seeded in 24-well plates at a 
density of  3x10
4
 cells / well for both cell lines. On the day of transfection, 200 ng of 
DNA/well was diluted in Buffer EC up to a final volume of 60µL. 1.6 µL of enhancer was 
added and the final mixture incubated at room temperature for 5 min. Following this 
incubation, 2µL of Effectene transfection reagent was added, followed by incubation at room 
temperature for 10 minutes, meanwhile the cells where re-fed with 500µl of new medium. 
Finally the DNA mixture was diluted with 200µl of fresh medium and the transfection 
complexes where transferred dropwise to the cells re-fed with new medium. Cells were 
incubated with the transfection mixture for 8 hours, after this period the cells were washed 
with PBS and fed with the induction medium. 
 
2.2.4. MAMMALIAN TWO HYBRID ASSAY 
Mammalian two hybrid is a method used to analyse protein-protein interactions. In this 
project we intended to study the ligand dependent interaction between the LBD of a specific 
nuclear receptor and the RID of a co-activator. For this purpose the LBD of the nuclear 
receptor was fused to the VP16-activation domain and the RID of the co-activator fused with 
the GAL4-DNA binding domain. In the presence of a specific ligand the interaction between 
the NR-LBD and the co-activator-RID is induced, bringing into close proximity the VP16-AD 
and the GAL4-DBD, forming an active transcription activation complex and inducing the 
expression of the reporter target gene, the firefly luciferase (Fig.9). Concomitant, the cells 
were also co-transfected with a plasmid containing a constitutively active -galactosidase, 
used as a transfection efficiency control. 
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Figure 9: Brief description of the mammalian two hybrid assay. 
 
Based on previously obtained data from our laboratory, two systems were chosen to study the 
ligand binding of the antimalarials to the xenosensors, PXR and CAR. (Burk et al., 2005). 
The selection of the co-activator to be tested was based on the previoulsy data from our lab, 
concerning interaction intensity. For these studies it was chosen the co-activator with the 
highest interaction values with the PXR/CAR, upon exposure to a prototypical ligand, namely 
rifampicin for PXR and CITCO for CAR. So, based on these criteria, it was chosen as targets 
of study the interactions between PXR and SRC1 and of CAR SV2 and PPARBP. These 
systems were used to perform an initial screening of the ligand capacity of the antimalarials 
and further to determine their specific EC50’s. For an initial screening two concentrations 
were used, 100µM and 10µM. Compounds that revealed an induction of the interaction 
between the nuclear receptor and the co-activator at this two initial concentrations, were 
further tested using five additional concentrations (1, 3, 30, 50 and 300µM) to determine the 
EC50’s by graphical analysis of the dose-response curves, using the GraphPad software. All 
compounds were tested using this system, except for the compounds from the artemisinin 
family in the PXR case that were already described as not inducing the interaction of co-
activators with PXR (Burk et al., 2005); for these compounds a gene reporter assay approach 
was used. 
Briefly, the plasmids described in table 7 were transfected into COS1 (CARSV2-PPARBP) or 
HeLa Cells (PXR-SRC1) according to the description in section 2.2.3. All transfection were 
performed in triplicates and repeated at least twice in independent experiments. 
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 Table 7: Plasmid amounts, used for the mammalian two hybrid assays.  
 
Plasmid name CARSV2-PPARBP PXR-SRC1 
pGL3-G5 0.10µg 0.10µg 
pCMVß 0.02µg 0.02µg 
pUC18 - 0.02µg 
pM-PPARBP 0.01µg - 
pVP16-CARSV2 0.08µg - 
pM-SRC1 - 0.05µg 
pVP16-PXR - 0.01µg 
Total amount 0.21µg 0.20µg 
 
 
The induction procedure was performed as described in section 2.2.6. 
 
2.2.5. GENE REPORTER ASSAY 
Reporter gene assays are powerful tools to access the regulation of a specific gene. In this 
technique the DNA regulatory region of interest is fused to a reporter gene, in our specific 
case, the firefly luciferase gene. The enzyme coded by this gene is able to catalyze a light 
emitting reaction. Upon induction by the promoter region under test, the light emitted is 
quantified as a direct measurement of the induction capacity of the molecule on study. 
If the cell line used for the assay did not express the transcription factor mediating the 
activation of the promoter region, it may be necessary to co-transfect an episomal expression 
vector carrying the gene coding for this protein. This was the situation in our system - the 
study of the induction of the promoter region of CYP3A4 by PXR. As COS1 cells do not 
express PXR, co-transfection of the pcDhuPXR expression plasmid carrying the gene for this 
nuclear receptor had to be performed.  
Briefly, COS1 cells were transfected as described in section 2.2.3, with the plasmids 
described in table 8. All transfection were performed in triplicates and repeated at least twice 
in independent experiments. 
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Table 8: Plasmid amounts, used for the gene reporter assay. 
 
Plasmid name Amount 
pGL3-CYP3A4 0.15µg 
pCMVß 0.02µg 
pUC18 0.02µg 
pcDhuPXR 0.01µg 
Total amount 0.20µg 
 
 The induction procedure was performed as described in section 2.2.6. 
 
2.2.6. INDUCTION BY ANTIMALARIALS OF THE MAMMALIAN TWO 
HYBRID AND GENE REPORTER SYSTEMS 
After 8 hours of incubation with the specific transfection complexes, the cells were treated 
with induction mediums. For the initial screening two concentrations of the antimalarials were 
tested, namely, 100µM and 10 µM. The compounds and their solvent (Me2SO) were diluted 
to their final concentration, in phenol red-free DMEM medium, supplemented with 10% FCS-
DCC (fetal calf serum that was previously treated with dextran-coated charcoal to eliminate 
steroids), 2mM L-glutamine and 1% of penicillin/streptomycin. The same was performed to 
assess dose-curve response curves for all compounds that revealed induction in the first 
screening. For the dose-curve response curves concentrations of 1, 3, 30, 50, and 300 µM 
were tested. After ~40h of induction the cells were harvested (see section 2.2.7.) and firefly 
luciferase and β-galactosidase activities were measure according to sections 2.2.7. and 2.2.8.  
 
2.2.7. CELL HARVESTING 
After ~40h of induction the cells were harvested by aspirating the medium and washing the 
cells twice with 500 μl 1x PBS. Cell lyses was performed using 150 μl 1x Passive Lyses Buffer 
(Promega) added to each well and incubated at room temperature for 20 min with shaking. The 
lysates were homogenized and centrifuged at 12000 x g. The samples were maintained on ice until 
the measurement of ß-galactosidase/luciferase activity was performed (alternatively the extracts 
can be stored at – 80°C in 24-well plates). 
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2.2.8. DETERMINATION OF THE FIREFLY LUCIFERASE ACTIVITY 
The firefly luciferase is an oxidative enzyme, which is frequently used for measuring 
promoter activity. This protein catalyzes luciferin oxidation, with concomitant emission of 
light which is measured using a luminometer. The quantitative level of light emission is 
proportional to the promoter activity of the reporter gene. 
For firefly luciferase activity determination, 20µl of the sample obtained from the mammalian 
two hybrid or gene reporter assay were transferred to a 4 ml tube. Meanwhile the reaction 
injection mix + was prepared and introduced in a luminometer. 
Reaction Injection Mix+ (RIM+): 0,005mM luciferin ; 2mM ATP ; 10mM MgCl2 ; 0,027mM coenzyme A ; 
DTT 10mM ; 25mM glycylglycine pH7.8  
 
2.2.9. DETERMINATION OF THE β-GALACTOSIDASE ACTIVITY 
This assay is based on fact that β-galactosidase is an enzyme that catalyzes the hydrolysis of 
β-galactosides into monosaccharides, in our particular case the hydrolysis of galacton, 
followed by light production at a pH>9.5. This was used to assay the efficiency of 
transfection. The assay was performed according to what was described by Jain and Magrath 
(1991) with modifications. Briefly, 10µl of cell extract was incubated with 100µl β-Gal assay 
buffer for 30 min followed by the injection of 300µl β-Gal assay stop buffer mix. 
Luminescence was measured for 5 sec in a luminometer Autolumat Plus (Berthold, Bad 
Wildbad, Germany) 
-Gal assay buffer: 100mM Na-phosphate pH 8.0 ; 1mM MgCl2 ; 1,25µg/ml galacton  
-Gal assay stop buffer: 0.2 M NaOH; 2.5% Emerald™ Enhancer  
 
 
2.2.10. COACTIVATOR-DEPENDENT RECEPTOR LIGAND ASSAY 
(C.A.R.L.A.) 
CARLA is an in vitro assay based on the principle that the binding of a ligand to a nuclear 
receptor will induce its interaction with a co-activator. The assay relies on the pull-down of a 
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GST-coactivator fusion protein interacting in a ligand-dependent way with an in vitro 
transcribed (35S-methionine-labelled) NR. The GST-complex is then immobilized to 
glutathione-sepharose beads. 
 
2.2.10.1. BACTERIAL EXPRESSION OF GST-FUSION PROTEINS 
The E.coki bacterial strain BL21 (DE3) pLysS was transformed with the plasmid enconding a 
fusion protein of GST and the human PPARBP-RID according to the protocol described in 
section 2.2.1.2. This strain allows a high-efficiency protein expression of any gene that is 
under the control of a T7 promoter and has a ribosome binding site. The bacteria were 
inoculated in 5ml of LB-Amp medium and incubated overnight at 37°C. On the following 
day, 50ml of LB-Amp medium were inoculated with 1.5ml of the pre-culture and further 
incubated at 37°C until the culture reaches an OD600 of 0.7-0.8. Following this period the 
culture was induced with 0.5mM IPTG (a molecular mimic of allolactose, a lactose 
metabolite that triggers transcription of the lac operon), and the bacteria were incubated for 
~20h at 16°C. 
The culture was then centrifuged at 4°C, 2000xg for 15 min. The bacterial pellet was diluted 
in 2.5ml of lysis buffer supplemented with protease inhibitors. The lysis was performed by 
freezing/thawing cycles in liquid N2. The bacteria were further sonicated on ice for 40 sec. To 
remove the bacterial debris a final centrifugation was performed at 4°C, 40000xg for 30 min. 
The supernatant, containing the recombinant protein, was stored at -80°C. 
Lysis Buffer: 20mM Tris-HCl pH8.0; 100mM NaCl; 1mM EDTA; 1mM DTT; 0.5% NP-40 (supplemented with 
protease inhibitors) 
 
2.2.10.2. BINDING OF GST-FUSION PROTEINS TO GLUTATHIONE-
SEPHAROSE BEADS 
Before usage, the glutathione-sepharose beads were washed 3 times with NETN buffer by 
centrifugation. After the final washing the beads were ressuspended in 1ml of NETN buffer.  
500µl of the beads were centrifuged and the supernatant removed. 2ml of the corresponding 
bacterial protein lysate (PPARBP) were added to the beads and incubated 1h at 4°C in an 
Material and Methods 
 
43 
 
over-head shaker. Finally the beads were washed 3 times with NETN and ressuspended in 
5ml NETN + 0.5%MM. 
Glutathione-Sepharose 4B (GE Healthcare # 17-0756-01): 75% slurry in 20% ethanol 
NETN buffer: 20 mM Tris-Cl pH 8.0 / 100 mM NaCl / 1 mM EDTA / 1 mM DTT / 0.5% NP-40 
NETN buffer + 0.5% MM: NETN / 0.5% (w / v) skimmed milk powder 
 
2.2.10.3. 35S-METHIONINE LABELING 
The labeling of CAR was performed according to the recommendations for in vitro 
transcription / translation of the TNT Quick Coupled Transcription / Translation Kit. 
 
2.2.10.4. BINDING REACTION OF GST-FUSION PROTEIN TO 35S-
LABELED PROTEIN 
To 0.5ml of the GST-protein-bead slurry in NETN + 0.5%MM was added 0.5ml NETN + 
0.5% MM, 2µl of CAR 35S-Met labelled and 10µl of the specific ligand (from a stock 
solution of 100x) or DMSO up to a final concentration of 1%. This mixture was further 
incubated in an over-head shaker for 4 hours at 4°C. The samples were then centrifuged and 
washed 3 times with NETN plus the specific ligand or DMSO. After the last washing the 
supernatant was completely removed and 35µl 1x Lämmli buffer + - mercaptoethanol were 
added to the pellet. The samples were stored at -80 °C until protein gel electrophoresis. 
 
2.2.10.5. PROTEIN GEL ELECTROPHORESIS AND ANALYSIS 
The final step of a C.A.R.L.A. assay is the analysis of the proteins in an polyacrylamide gel. 
For this purpose a sodium dodecyl sulfate polyacrylamide gel electrophoresis was performed. 
After preparing the specific gel, 30µl of pre-boiled sample was loaded. As an input control it 
was also loaded 10µl of the corresponding 35S-Met labelling-reaction (1:50 diluted in 1x 
Lämmli buffer + - mercaptoethanol). 
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After the electrophoresis the gel was stained for 15 min in Coomassie, de-stained for 45 min, 
and finally it was washed with water. In a final step the gel was incubated for 30 min in 0.5M 
Na-slicylate. Following this steps the gel was dried for 1h, and exposed to an image-plate 
over-night. 
Coomassie-staining solution: 0.125% Coomassie Brilliant Blue / 45% ethanol / 10% acetic acid 
fixing / destaining: 9% ethanol / 6% acetic acid  
 
2.2.11. INDUCTION EXPERIMENTS WITH PRIMARY HUMAN 
HEPATOCYTES 
 
2.2.11.1. HUMAN PRIMARY HEPATOCYTES CULTURE AND 
INDUCTION 
The hepatocytes used in this study were isolated from liver tissue and cultivated as reported 
elsewhere (Yuan et al., 2004). The isolation procedure was performed by the provider. 
After arrival the hepatocytes were supplied with pre-warmed WilliamsE/ITS/Dex culture 
medium. 24 hours after this initial medium change the induction was started by adding fresh 
medium containing the respective inducers and solvent controls. For amodiaquine and 
desethylchloroquine a treatment of only 24 hours was performed due to toxicity of the 
compounds. For all other inducers tested cells were re-fed after ~24h and cells were induced 
for ~48hours. After induction the cells were processed for RNA extraction. 
WilliamsE/ITS/Dex culture medium: 10nM dexamethasone; 2mM L-glutamine; 1% ITS-G; 100U/ml 
penicillin; 100mg/ml streptomycin 
 
2.2.11.2. RNA EXTRACTION 
At the end of the induction phase, cells were washed once with PBS. Cells were lysed in 
600µl of lysis/binding buffer (mirVana  Kit). The extraction was performed according to the 
instructions of the manufacturer.  
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2.2.11.3. ASSESSMENT OF RNA QUALITY AND QUANTITY 
RNA quality was assessed by the integrity and intensity of the 28S and 18S bands observed 
by electrophoresis in a denaturating agarose gel. For this purpose a 1% agarose gel was 
prepared, by dissolving the agarose in 1xMOPS running buffer and DEPC water containing 
0.365M formaldehyde. The samples were prepared by adding 0.15-0.5µg of RNA to RNA 
sample buffer dye to a volume of 16µl, 0.8µl of ethidium bromide (0.5µg/µl) was also added. 
This sample was heat denaturated at 60°C for 10 minutes, and chilled on ice. Prior to loading 
the gel, 4µl of RNA loading dye containing bromophenol blue was added to the samples. The 
electrophoresis was performed in 1x MOPS running buffer at 4V/cm. The RNA was 
visualized on a UV transilluminator. The integrity of the RNA was assessed by observation of 
sharp 28S and 18S bands and by observing a ratio of intensity of 2:1 (28S:18S). 
RNA was further quantified using a Nanodrop. 
 
1x MOPS Buffer: 20mM MOPS pH 7.0; 1mM EDTA; 5mM Na-acetat pH 7.0 adjusted with NaOH 
RNA sample buffer: 50% deionised formamid; 1xMOPS buffer; 2.2M formaldehyde. 
RNA loading dye: 10% ficoll; 0.1% bromophenolblue 
 
2.2.12. QPCR (TAQMAN) 
2.2.12.1. CDNA SYNTHESIS 
For the synthesis of cDNA from human hepatocytes the TaqMan reverse transcription 
reagents were used according to the manufacturer’s instructions. Briefly, 1µg of total RNA 
was mixed with the following reagents: 5µl 10x TaqMan RT Buffer, 11µl MgCl2 (25mM), 
10µl dNTP Mix (2.5mM each), 2.5 µl random hexamers (50µM), 1µl RNase inhibitor, 1.25 µl 
MultiScribe reverse transcriptase (50U/µl) and RNase-free water up to a total volume of 50µl. 
This mixture was incubated for 10 minutes at 22°C for the annealing of the random hexamers. 
This initial incubation was followed by an additional incubation at 48°C for 1 hour and an 
enzyme inactivation at 95°C for 5 min. The cDNA was diluted to a final concentration of 
5ng/µl and stored at -20°C. 
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2.2.12.2. QUANTITATIVE REAL-TIME PCR (TAQMAN
®
) 
TaqMan
®
 quantitative real-time PCR was developed to increase specificity in real-time PCR 
assays. Shortly, this method relies on the 5’-3’ nuclease activity of Taq polymerase to cleave 
a dual labeled probe. This probe is labeled with a fluorophore at the 5’-end and a quencher at 
the 3’-end. Upon probe cleavage by Taq Polymerase, physically displacing the quencher from 
the fluorophene, the latter is allowed to emit fluorescence after excitation by the cycler’s light 
source. The resulting signal allows the quantitative measurement of the accumulation of the 
amplification product during the exponential stages of the PCR.  
TaqMan
®
 -based quantitative real-time PCR was used to quantify the expression of the genes 
under study in induced primary human hepatocytes. The specific sequences and labels of the 
oligonucleotides are described in table 5. A calibration curve was used in parallel to the 
samples, allowing absolute quantification. This calibration curve was obtained by serial 
dilution of linearized plasmids containing the cDNA of the genes of interest.  
The reactions were performed according to the standard protocol for the ABI PRISM 7500 
Sequence Detection System (Applied Biosystems, Foster City, USA). The assay conditions 
are listed in table 5. All samples were measured in triplicate and induction values were 
obtained using the absolute quantification method, after normalization with the normalizing 
gene (18S rRNA coding gene). 
 
2.2.13. DETERMINATION OF GENETIC VARIABILITY IN PXR.  
2.2.13.1. DESCRIPTION OF THE SAMPLES 
Samples used in sub-project 2 were obtained from a clinical study previously described by 
Asimus and colleagues. Briefly, 75 healthy volunteers (51 men and 24 women) were 
repeatedly treated with one of the following artemisinin drugs; artemisinin (500 mg), DHA 
(60 mg), artemeether (100 mg), arteether (100 mg) or artesunate (100 mg) for five days (day 1 
-5). A cocktail of six probe drugs, caffeine (100 mg), coumarin (5 mg), mephenytoin (100 
mg), metoprolol (100 mg), chlorzoxazone (250 mg) and midazolam (7.5 mg), were given 
orally six days before (day -6) administration of the artemisinin drugs. On day 1 and day 5 of 
artemisinin drug intake, the cocktail drugs were given again, 1 hour after the artemisinin 
drugs. The cocktail drugs were then administered once more after a wash-out period of five 
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days (day 10). Probe compounds were measured in blood samples taken immediately before, 
and at 4 hours after administration of the cocktail drugs on days -6, 1, 5 and 10 (Figure 10). 
 
Figure 10: Description of the clinical study. 
DNA was extracted from these samples, and further analysed. 
 
2.2.13.2. WHOLE GENOME AMPLIFICATION  
In recent years a new PCR based technique has arisen that allows the replication of the entire 
DNA of a specific sample, from very limited starting material. 
Due to the lack of sufficient amounts of DNA, whole genome amplification was performed 
with the samples.  The amplification was performed as described in the protocol provided 
with the illustra GenomiPhi  V2 DNA Amplification Kit. Briefly, 3-5µl of each sample was 
dried overnight in an open 96 well plate. After this step, the samples were re-hydrated with 1 
µl of Sigma Delta Select water and 9 µL of sample buffer, and the DNA was denaturated for 3 
min at 95°C, and cooled to 4°C. To each cooled sample 9µl of reaction buffer and 1 µl of 
enzyme mixtures were added. Samples were then incubated at 30°C for 1.5 hours and 
subjected to an enzyme heat inactivation for 10 min at 65°C. In parallel to our samples, a “no 
template control” was used, to ensure that all solutions in the protocol were DNA free. 
After amplification, samples were diluted to 10 fold with water. The efficiency of the whole 
genome amplification was determined by PCR. 
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2.2.13.3 AMPLIFICATION OF DNA FRAGMENTS AND RE-SEQUENCING 
Our approach to study the genetic variability of PXR was to re-sequence all exons, the 3’UTR 
region and 1kb of the 5’ promoter region (Figure 11). PCR assays were developed to analyze 
these regions. For that purpose specific oligonucleotides were either newly developed or used 
from already published data. The newly developed primers were designed according to the 
sequence AF364606 (table 4). 
 
 
 
 
Figure 11: Linear graphic representation of the PXR gene, with all the amplified fragments annotated. 
The arrows symbolize the position of the specific oligonucleotides. It is also highlighted the position of the 
coding regions for the DBD (DNA binding domain) and the LBD (ligand binding domain) of PXR. The white 
boxes represent the 1kb of the promoter region and the 3’UTR region. 
 
The amplifications were performed in a GenAmp  PCR System 2700 (Applied Biosystems, 
Fresno, CA, USA). Each amplification reaction started with an denaturation step at 95°C for 2 
min, followed by a cycle, repeated 40x, of 30sec at 94°C, 30 sec at the specific annealing 
temperature (see table 6), and 60 sec at 72°C, the PCR reaction ending with a final extension 
of 5’ min at 72°C. The amplifications were performed in a master mix containing, 1x GoTaq  
reaction buffer, 0.2µM of each dNTP, 0.4µM of each specific primer and 1.25U of GoTaq  
polymerase. After amplification the presence of the specific fragment was confirmed in a 2% 
agarose gel. All amplicons were sequenced by Macrogen Inc. (www.macrogen.com, Seoul 
University, Seoul, South Korea). All PCR fragments were single strand sequenced; the 
specific primers used for sequencing are annotated in table 4. 
        
1a 1b 2 3 4 5 6 7 8 9 
DBD LBD 
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3. RESULTS 
3.1. STUDY OF THE CAPACITY OF CURRENTLY USED ANTIMALARIAL 
DRUGS TO ACTIVATE THE PXR/CAR XENOBIOTIC SIGNALLING 
PATHWAY. 
 
3.1.1. ACTIVATION OF PXR  BY ANTIMALARIALS 
 
3.1.1.1. SCREENING 
A mammalian two hybrid assay was used to study the induction of the interaction of PXR 
with the co-activator protein SRC1, upon treatment with antimalarials. All available 
antimalarials were tested, together with the induction control, rifampicin. The values obtained 
for each compound were normalized to a control performed with the respective concentration 
of the vehicle (Me2SO). Due to their toxicity at screening concentrations (10 and 100µM) in 
HeLa cells, mefloquine, dihydro-artemisinin and pyronaridine were removed from the study. 
Data concerning all other compounds screened is described in Figure 12. 
A cut-off value of 2 fold induction was defined to be the minimum value to consider a drug as 
inducing the interaction of PXR with SRC1. In this assay the compounds above this cut-off 
value were lumefantrine (mean F.I. = 3.59±1.71), carboximefloquine (mean F.I. = 3.38±1.21), 
chloroquine (mean F.I. = 2.13±0.48), at the maximum concentration tested (100µM), DEAQ 
(mean F.I. = 2.57±0.70) and amodiaquine (mean F.I. = 2.08±0.56) at 10 µM. For these two 
compounds data is not available for the 100 µM concentration due to their observed toxicity. 
Taken these fold inductions in consideration, these 5 compounds were further tested in a 
dose-response study. Results are described in chapter 3.1.1.2. 
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Figure 12: Modulation of the interaction of PXR with the co-activator SRC1 by antimalarials, in a 
mammalian two hybrid assay. Two concentrations were analyzed (10 and 100 M). The horizontal bars 
represent the mean induction factors (  S.D.). The baseline activity of the nuclear receptor in the presence of the 
co-activator, treated only with Me2SO (negative control) was defined as 1.  
 
The compounds of the artemisinin family were previously described as not inducing 
significantly the interaction of PXR with SRC1 in a mammalian two hybrid assay (Burk et al., 
2005), hence were not analyzed by this approach. For this class of compounds a reporter gene 
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assay was further performed, by co-transfecting the expression plasmids encoding for human 
PXR and the CYP3A4 promoter gene reporter plasmid into COS1 cells. In this assay 
artemisinin, arteether, artemether, deoxy-arteether and deoxy-artemisinin showed induction of 
the nuclear receptor PXR. Artemisinin had the highest induction at 100µM (mean F.I. = 
4.12±1.08), but did not show significant induction at the lower concentration of 10µM (mean 
F.I. = 0.90±0.10). Both arteether and artemether show induction at both 100 µM (ARE mean 
F.I. =3.04±0.64; ARM mean F.I. =2.61±0.44) and 10 µM (ARE mean F.I. =2.25±0.32; ARM 
mean F.I. =1.63±0.07). No induction was observed at both concentrations tested for 
artesunate, and at the lowest concentrations of deoxy-arteether and deoxy-artemisinin (Figure 
13). 
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Figure 13: Screening by gene reporter assay of artemisinin and its derivatives ligand capacity for PXR. 
Columns show the mean induction factors (  S.D.). The activity of the nuclear receptor in the presence of 
Me2SO (negative control) was given the value 1.  
 
3.1.1.2. EC50 DETERMINATION 
From the initial screening, all the compounds with fold induction above 2 were chosen to be 
tested in a dose-response assay in order to further confirm induction of the nuclear receptor 
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PXR at different drug concentrations, and to determine their specific half maximal effective 
concentration (EC50). This value represents the concentration of agonist necessary to reach 
50% of the maximum induction.  
Briefly, this value was determined by performing a dose-response curve, using 7 different 
concentrations (1, 3, 10, 30, 50, 100, 300µM) of the compounds, using the same assays as 
applied for their screening. The EC50’s were extrapolated using the software GRAPHPAD 
PRISM5, plotting the log concentration antimalarial vs. response (fold induction), in cases 
where the plateau phase of induction was not reached, the presented EC50 value is only a 
graphically approximation. The specific values obtained for these compounds are shown in 
table 9. 
 
Table 9: Dose-response analysis of PXR activation by antimalarials. Data obtained by gene reporter assays 
for the artemisinins; mammalian two-hybrid assay for the other antimalarials. Several concentrations of 
compounds were tested (1, 3, 10, 30, 50, 100, 300µM). Results were obtained using the software GRAPHPAD 
PRISM5, and are presented as mean  95% CI.  
 
 
Compound EC50(95% CI ) M Maximum fold 
induction 
Maximum 
concentration( M) 
Artemisinin 53.54 (11.46-250.20) 4.12 100 
Arteether 8.92 (3.62-21.98) 3.18 30 
Artemether 14.15 (10.32-19.42) 3.41 50 
Deoxy-Arteether 32.03 (24.46-41.94) 2.02 100 
Deoxy-Artemisinin 25.13 (18.74-33.71) 2.48 300 
Lumefantrine > 64 3.56 100 
Carboximefloquine 27.44 (10.70-70.34) 3.37 300 
DEAQ  > 20 41.18 30 
Chloroquine > 54 2.13 100 
Amodiaquine 17.20 (0.53 – 556.50) 34.50 50 
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3.1.2. ACTIVATION CAPACITY OF CAR BY ANTIMALARIALS 
 
3.1.2.1. SCREENING  
For this nuclear receptor a mammalian two hybrid assay was used, to screen the influence of 
the antimalarials on the interaction of the ligand-dependent CAR splice variant CAR-SV2 
with the co-activator DRIP 205. In this assay CITCO was used as the positive induction 
control. The values obtained for each compound were normalized to a control performed with 
the respective concentration of the vehicle (Me2SO). 
In this assay atovaquone, debutyl-benflumetol, pyrimethamine and pyronaridine were 
removed from the study due to their high toxicity in COS1 cells at both concentrations tested 
(10 and 100µM). 
A cut-off value of 2 fold induction was defined to be the minimum induction to consider a 
drug as inducing the interaction of CARSV2 with DRIP205. This group of drugs includes 
artemether with fold induction of 106.90±28.50 and 29.60±1.27, respectively at 100 and 
10µM, arteether, also inducing the interaction at both concentrations (mean F.I. 
=102.00±15.56 (100µM); mean F.I. =40.45±2.48 (10µM)). The metabolites deoxy-arteether 
(mean F.I. = 68.65±0.07 (100µM); mean F.I. =15.73±18.20 (10µM)) and deoxy-artemisinin 
(mean F.I. =62.10±36.44 (100µM); mean F.I. =7.36±6.05 (10µM)) also induced CAR. The 
parent compound, artemisinin induced the interaction at 100 µM (mean F.I. =33.43±21.35). 
Together with these compounds, amodiaquine at a concentration of 100 µM (mean F.I. 
=34.65±17.76) was also able to induce the interaction of CARSV2 with DRIP205 (Fig.14). 
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Figure 14: Antimalarial modulation of the interaction of CAR-SV2 with the co-activator DRIP205 by 
mammalian two hybrid. Two concentrations were analyzed 10 and 100 M. Columns show the mean induction 
factors (  S.D.). The activity of the nuclear receptor in the presence of the co-activator treated only with Me2SO 
(negative control) was given the baseline value of 1.  
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3.1.2.2. EC50 DETERMINATIONS 
All the compounds with fold induction above 2 were further tested in a dose-response assay in 
order to confirm induction of the nuclear receptor CAR at different drug concentrations, and 
to determine their specific half maximal effective concentration (EC50).  
Briefly, this value was determined by performing a dose-response curve, using 7 different 
concentrations (1, 3, 10, 30, 50, 100, 300µM) of the compounds and EC50 were extrapolated 
using the software GRAPHPAD PRISM5, plotting the log concentration antimalarial vs. 
response (fold induction). If the plateau phase of induction was not reached, the presented 
EC50 value is only a graphically approximation. The specific values obtained for these 
compounds are showed in table 10. 
 
Table 10: Dose-response analysis of the induction of CAR-SV2 interaction with DRIP205 by antimalarials. 
Data obtained by mammalian two hybrid assay. Results are presented as mean  95% CI. In cases where the 
plateau phase of induction was no reachable, EC50 value is only a graphically approximation, and CI was not 
determined. 
 
 
 
 
 
 
Compound EC50 ( M) Maximum 
fold 
induction 
Maximum 
concentration( M) 
Amodiaquine > 85 49.04 100 
Arteether 20.19 (16.23 – 25.12) 249.93 50 
Artemeether 12,44 (0.95 – 162.60) 105.85 100 
Artemisinin 71,26 (57.56 – 88.21) 62.52 300 
Deoxy-
Artemisinin 
> 141 270.30 300 
Deoxy-Arteether 48.48 (21.19 – 110.90) 82.26 300 
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3.1.2.3. IN VITRO INDUCTION STUDIES  
For further confirmation of assess the capacity of CAR by the artemisinins and amodiaquine, 
an in vitro approach was used. For this purpose a C.A.R.L.A. assay was performed using the 
same concentrations of ligands as for the previous assays. No induction was observed for 
these compounds, except for the induction control CITCO and arteether (Figure 15). Due to 
this fact, this approach was not further continued and only one experiment was performed. 
Further increases in the concentrations of ligands would probably be necessary to obtain 
induction by these compounds in this system. 
 
 
Figure 15: In vitro induction of selected antimalarials.  Data was obtained performing a CARLA assay. In the 
image is also shown the original IP. 
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3.1.3. INDUCTION OF KEY DME’S IN HUMAN HEPATOCYTES BY 
SELECTED ANTIMALARIALS.  
Further induction studies were performed to access the capacity of these drugs to interact with 
PXR and CAR in vivo, in this particularly case in primary human hepatocytes. For this study 
the expression of 3 known PXR/CAR target genes, CYP3A4, CYP2B6 and MDR1, were 
measured by real time RT-PCR, upon treatment with the antimalarials.  
The concentrations to be tested were chosen to be the highest not showing toxicity, asseessed 
by microscopic inspection, in the dose-response analysis. In this study dihydro-artemisinin 
was also included, due to the fact that is was described as non-toxic in primary human 
hepatocytes (Burk et al., 2005). Induction controls were performed with the prototypical PXR 
and CAR ligands, rifampicin and CITCO, repectively. The induction values were also 
normalized with the values for the dilution vehicle alone Me2SO (negative control). 
Taking in consideration that the hepatocyte cultures were derived from different donors and 
thus may show interindividual variability in response, and that only a very small number of 
cultures was used, statistical analysis was not performed. Thus the compounds were regarded 
as inducing/repressing, if the majority of the cultures were modulated accordingly. The 
cultures were considered as induced if an increase of 1.50 fold in induction and repressed if a 
decrease of 0.67 in expression upon treatment with the respective antimalarial, as compared to 
expression in the presence of Me2SO only, was observed (table11). 
 For CYP3A4 we could see a clear induction by the prototypical inducers, rifampicin and 
CITCO, at all tested conditions. A clear repression of this P450 was observed for 
amodiaquine (24h), with all 3 cultures being repressed (mean F.I. = 0.48±0.11). The same was 
observed for DEAQ, with 2 of the cultures being clearly repressed (mean F.I. = 0.55±0.28). 
No clear tedency of induction was observed for carboximefloquine, chloroquine and 
lumefantrine.  All artemisinin compounds, except artesunate and DHA, were inducing in all 
cultures. The highest mean fold induction was observed for artemisinin (11.73±7.17), folowed 
by artemether (10.25±6.07), deoxy-artemisinin (4.11±1.52), arteether (4.05±1.81) and deoxy-
arteether (3.04±0.74).  Both artesunate and DHA were repressing in this set of hepatocytes: 
artesunate was repressing in all cultures (mean F.I. = 0.59±0.35) and DHA was repressing in 
3 out of 5 cultures with a mean repression of 0.50±0.33 (Figure 16). 
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Also for CYP2B6 a clear induction by the prototypical inducers, rifampicin and CITCO, was 
observed. Regarding amodiaquine, no clear induction tendency was observed, being the 
results very divergent between cultures. Its metabolite DEAQ clearly repressed the expression 
of CYP2B6 in 2 of the 3 cultures studied (mean F.I.= 0.59±0.17). A clear induction was 
observed for carboximefloquine with a mean fold indution of 7.52±8.30. No clear conclusion 
regarding the regulation of CYP2B6 expression by chloroquine, lumefantrine and artesunate 
could be obtained. The highest induction of CYP2B6 was observed by the treatment with 
artemisinin (mean F.I. 9.85±7.77), the other compounds from this family had lower 
inductions, e.g., deoxy-arteether (mean F.I. 7.10±3.11), deoxy-artemisinin (mean F.I. 
6.05±1.60), artemether (mean F.I. 5.68±2.04) and arteether (mean F.I. 2.89±1.60). A clear 
repression of CYP2B6 expression was observed by the treatment with DHA in 3 of the 5 
cultures (mean F.I. 0.65±0.43) (Figure 16). 
Induction of the expression of MDR1 was not as efficient as for the other two genes. 
Induction was not observed in all cultures for the ligands rifampicin and CITCO (Table11).  
No clear induction or repression was observed for amodiaquine, DEAQ, carboximefloquine, 
chloroquine, lumefantrine, deoxy-artemisinin, deoxy-arteether and artesunate. Induction of 
the expression of this gene was clearly observed for artemisinin (mean F.I. 2.50±1.50), and 
arteether (mean F.I. 2.63±1.59). For artemether and DHA, induction was only observed in 2 
out of 5 cultures, with mean fold inductions of respectively, 2.22±1.46 and 1.60±0.72 (Figure 
16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
 
Table11: Summary of the induction of gene expression by antimalarials.  Cultures were considered to be 
induced above the thresholf of 1.5-fold inductions, and repressed bellow the threshold 0.67. 
 
 CYP3A4 CYP2B6 MDR1 
Xenobiotic Induction 
responsive 
cases 
Repression 
responsive 
cases 
Induction 
responsive 
cases 
Repression 
responsive 
cases 
Induction 
responsive 
cases 
Repression 
responsive 
cases 
Rifampicin 12/12 0/12 12/12 0/12 11/12 0/12 
Rifampicin (24h) 3/3 0/3 3/3 0/3 2/3 0/3 
Rifampicin 
(0.8%Me2SO) 
3/3 0/3 3/3 0/3 1/3 0/3 
CITCO 3/3 0/3 3/3 0/3 0/3 0/3 
Amodiaquine 1/4 2/4 1/4 1/4 2/4 1/4 
Amodiaquine (24h) 0/3 3/3 0/3 1/3 0/3 0/3 
DEAQ 0/3 2/3 0/3 2/3 0/3 1/3 
Carboximefloquine 1/3 1/3 3/3 0/3 1/3 0/3 
Chloroquine 1/3 1/3 0/3 1/3 1/3 0/3 
Lumefantrine 0/3 1/3 1/3 1/3 0/3 1/3 
Artemisinin 8/8 0/8 8/8 0/8 6/8 0/8 
Deoxy-arteminin 3/3 0/3 3/3 0/3 1/3 0/3 
Arteether 5/5 0/5 4/5 0/5 3/5 0/5 
Deoxy-arteether 3/3 0/3 3/3 0/3 0/3 0/3 
Artemether 5/5 0/5 5/5 0/5 2/5 0/5 
Artesunate 0/3 3/3 0/3 0/3 0/3 0/3 
DHA 0/5 3/5 0/5 3/5 2/5 0/5 
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Figure 16: Induction of CYP3A4, CYP2B6 and MDR1 mRNA expression by treatment of different 
antimalarials. Primary hepatocytes were derived from 3-12 donors. Except if otherwise stated, the cultures were 
treated for 48 hours. The expression was analyzed by real time RT-PCR and normalized to the 18S sRNA 
expression. Data represents fold induction relative to the vehicle, 0.1% Me2SO alone (if different, it is stated in 
the graphic). 
 
3.2. STUDY OF THE GENETIC VARIABILITY IN PXR IN A 
VIETNAMESE POPULATION 
Re-sequencing of all PXR exons, flanking intronic regions and 1kb of the promoter region 
was performed in all 75 healthy Vietnamese individuals included in the Asimus et al., 2007 
clinical study. Drop-outs were observed for some SNPs due to technical problems during 
sequencing and limited amount of DNA sample. Data was obtained by MALDI-TOF-MS by 
Dr. Elke Scheffler, Dr.Margarete Fischer Bosch-Institute of Clinical Pharmacology, Stuttgart, 
Germany, for further selected SNPs located in the promoter and intron1. 
This method allowed the study of 79 SNPs, but only 32 of them are present in this population 
in a polymorphic form, with  minor allelic frequency >0.01. Six of these polymorphism were 
not described in previously published data, being to our knowledge newly identified SNPs, 
namely; - 24910 G>A and -23925 C>T, in the promoter regions of PXR-1 and PAR2 
respectively; 8582T>G in the intronic region; 9915T>A (F420Y) in the open reading frame; 
finally 10098 C>T and 10976 G>A in the 3’ UTR region. Data concerning the genotypic and 
allelic frequencies of these SNPs is provided in table 12, a complete list of all SNPs studied in 
these samples, including the ones observed as monomorphic in this population are found in 
appendix 2. All SNPs with MAF >0.01% are described in figure 17. 
Among the SNPs identified -4356 T>C, 7635 A>G, 10331 A>G and 10483 T>C were the 
highest prevalent with minor allelic frequencies above 0.50, being the most common 
polymorphic alleles in this population. The newly identified SNPs, 8582 T>G and 10976 
G>A showed minor allelic frequencies above 0.20. All other newly identified SNPs were only 
found in a heterozygous form in one individual, hence with allele frequencies below 1%. 
All SNPs, except PXR 8055 C>T and 10976 G>A were in Hardy –Weinberg equilibrium. The 
assessment of the Hardy-Weinberg equilibrium was performed using the chi-squared test and 
fisher exact test in the GraphPad Quickcalcs software (data not shown).  
  
Table 12: Genotyping data of the Vietnamese Population for SNPS with MAF>0.01.  Genotype and allele frequencies are described, as well as their position and number 
of individuals analyzed; c Value in parenthesis is the 95% confidence interval determine with GraphPad Quickcalcs.In red are described the SNPs newly identified, and in 
blue SNPs genotyped by MALDI-TOF-MS. 
     Allele frequency 
c
 Genotype frequencies 
c
 
Position 
a
 Putative effect Identifier Sequence N 
b
 wt mut wt/wt wt/mut mut/mut 
-25913 C>T STAT1, 3, 6 and 
NAT binding sites 
  71 0.84 
(0.77-0.89) 
0.16 
(0.11-0.23) 
0.70 
(0.59-0.80) 
0.27 
(0.18-0.38) 
0.03 
(0.00-0.10) 
-25385 C>T NFKB, ISGf-3 
binding sites 
rs3814055 CAGGTT[C/T]TCTTTT 75 0.83 
(0.76-0.88) 
0.17 
(0.12-0.24) 
0.69 
(0.58-0.79) 
0.28 
(0.19-0.39) 
0.03 
(0.00-0.10) 
- 24910 G>A Lost of Oct-1 
binding site anda 
CCAAT box 
 TGATTG[G/A]CACCGT 75 0.99 
(0.96-0.99) 
0.01 
(0.00-0.04) 
0.99 
(0.92-0.99) 
0.01 
(0.00-0.08) 
0.00 
(0.00-0.06) 
-24381 A>C  rs1523127 CCTGAA[A/C]AAGGCA 75 0.83 
(0.76-0.88) 
0.17 
(0.12-0.24) 
0.69 
(0.58-0.79) 
0.28 
(0.19-0.39) 
0.03 
(0.00-0.10) 
-23925 C>T   TACCAC[C/T]TCCAAG 56 0.99 
(0.94-1.00) 
0.01 
(0.00-0.05) 
0.98 
(0.89-1.00) 
0.02 
(0.00-0.10) 
0.00 
(0.00-0.08) 
-23913 T>G  rs3814056 GGACTG[T/G]GGGAGC 56 0.71 
(0.61-0.78) 
0.29 
(0.22-0.38) 
0.48 
(0.36-0.61) 
0.45 
(0.32-0.58) 
0.07 
(0.02-0.17) 
-14042 C>A DR3 bindingsite   71 0.65 
(0.57-0.73) 
0.35 
(0.27-0.43) 
0.41 
(0.30-0.53) 
0.49 
(0.38-0.61) 
0.10 
(0.05-0.19) 
-4356 T>C    69 0.33 
(0.25-0.41) 
0.67 
(0.59-0.75) 
0.09 
(0.04-0.18) 
0.48 
(0.36-0.59) 
0.43 
(0.32-0.55) 
-601A>G HNF4 binding site   70 0.56 
(0.47-0.64) 
0.44 
(0.36-0.53) 
0.31 
(0.22-0.43) 
0.49 
(0.37-0.60) 
0.20 
(0.12-0.31) 
  
252 A>G  rs1464603 GGTAAC[A/G]TCTCAG 75 0.55 
(0.47-0.62) 
0.45 
(0.38-0.53) 
0.29 
(0.20-0.41) 
0.51 
(0.40-0.62) 
0.20 
(0.12-0.30) 
275 A>G  rs144602 TGACCT[A/G]TCCCCC 75 0.57 
(0.49-0.65) 
0.43 
(0.35-0.51) 
0.32 
(0.23-0.43) 
0.51 
(0.40-0.62) 
0.17 
(0.10-0.28) 
308 A>T   TGGCCC[A/T]CCCAAA 75 0.99 
(0.96-1.00) 
0.01 
(0.00-0.04) 
0.99 
(0.92-1.00) 
0.01 
(0.00-0.08) 
0.00 
(0.00-0.06) 
3015 T>G   GGTGTG[T/G]GCATGC 61 0.84  
(0.76-0.89) 
0.16 
(0.11-0.24) 
0.74 
(0.62-0.83) 
0.19 
(0.12-0.32) 
0.07 
(0.02-0.16) 
5761 A>G   GTGGCC[A/G]GGAGGT 67 0.99 
(0.94-1.00) 
0.01 
(0.00-0.06) 
0.97 
(0.89-1.00) 
0.03 
(0.00-0.11) 
0.00 
(0.00-0.07) 
7635 A>G  rs6785049 CCTCTC[A/G]CCCCCA 66 0.41 
(0.33-0.49) 
0.59 
(0.51-0.67) 
0.18 
(0.11-0.29) 
0.45 
(0.34-0.57) 
0.36 
(0.26-0.48) 
7675C>T  rs6797879 TGCCGG[T/C]CTGTGG 67 0.81 
(0.74-0.87) 
0.19 
(0.13-0.26) 
0.67 
(0.55-0.77) 
0.28 
(0.19-0.40) 
0.04 
(0.01-013) 
8055C>T  rs2276707 CTCCAT[C/T]CTGTTA 73 0.60 
(0.52-0.67) 
0.40 
(0.33-0.49) 
0.44 
(0.33-0.55) 
0.31 
(0.22-0.43) 
0.25 
(0.16-0.36) 
8118 C>T  
 
Y328Y rs2229856 CCACTA[C/T]ATGCTG 68 0.74 
(0.66-0.80) 
0.26 
(0.20-0.35) 
0.47 
(0.36-0.59) 
0.53 
(0.41-0.64) 
0.00 
(0.00-0.06) 
8582T>G   CATAGG[T/G]GAGCAC 70 0.79 
(0.72-0.85) 
0.21 
(0.15-0.28) 
0.59 
(0.47-0.70) 
0.41 
(0.31-0.53) 
0.00 
(0.00-0.06) 
9863A>G I403V  CGCAGC[A/G]TCAATG 60 0.99 
(0.95-1.00) 
0.01 
(0.00-0.05) 
0.98 
(0.90-1.00) 
0.02 
(0.00-0.10) 
0.00 
(0.00-0.07) 
9915T>A F420Y  ACCCCT[T/A]TGCTAC 65 0.99 
(0.95-1.00) 
0.01 
(0.00-0.05) 
0.98 
(0.91-1.00) 
0.02 
(0.00-0.09) 
0.00 
(0.00-0.07) 
     9932C>G Q426 E rs56162473 CTCATG[C/G]AGGAGT 65 0.98 
(0.94-1.00) 
0.02 
(0.00-0.06) 
0.97 
(0.88-1.00) 
0.03 
(0.00-0.11) 
0.00 
(0.00-0.07) 
  
   9976G>A  rs3732358 CCTTGG[G/A]TGACAC 68 0.98 
(0.95-1.00) 
0.01 
(0.00-0.06) 
0.97 
(0.89-1.00) 
0.03 
(0.00-0.11) 
0.00 
(0.00-0.06) 
9987G>A   ACCTCC[G/A]AGAGGC 68 0.99 
(0.96-1.00) 
0.01 
(0.00-0.05) 
0.98 
(0.91-1.00) 
0.02 
(0.00-0.09) 
0.00 
(0.00-0.06) 
10058C>G   AAGAGC[C/G]GACAAT 65 0.98 
(0.94-1.00) 
0.02 
(0.00-0.06) 
0.97 
(0.88-1.00) 
0.03 
(0.00-0.11) 
0.00 
(0.00-0.07) 
10098 C>T   TTCCTG[C/T]TATGAC 71 0.99 
(0.96-1.00) 
0.01 
(0.00-0.04) 
0.99 
(0.92-1.00) 
0.01 
(0.00-0.08) 
0.00 
(0.00-0.06) 
10331A>G  rs3732359 AAGGAT[A/G]GGCCAT 68 0.36 
(0.28-0.44) 
0.64 
(0.56-0.72) 
0.22 
(0.14-0.33) 
0.28 
(0.19-0.40) 
0.50 
(0.38-0.62) 
10483 T>C  rs3732360 GGCAGG[C/C]GCATGA 66 0.36 
(0.29-0.45) 
0.64 
(0.55-0.71) 
0.23 
(0.14-0.34) 
0.27 
(0.18-0.39) 
0.50 
(0.38-0.62) 
10719 A>G  rs6438550 ACAAAC[A/G]ATTTGG 64 0.82 
(0.74-0.88) 
0.18 
(0.12-0.26) 
0.75 
(0.63-0.84) 
0.14 
(0.07-0.25) 
0.11 
(0.05-0.21) 
10976 G>A   GGCTAC[G/A]CTGACA 75 0.65 
(0.57-0.72) 
0.35 
(0.38-0.43) 
0.29 
(0.20-0.41) 
0.71 
(0.60-0.80) 
0.00 
(0.00-0.06) 
11156 A>C  rs3814057 CACCTA[A/C]GAACTA 75 0.56 
(0.48-0.64) 
0.44 
(0.36-0.52) 
0.40 
(0.30-0.51) 
0.32 
(022-0.43) 
0.28 
(0.19-0.39) 
11193 T>C  rs3814058 TTAATG[T/C]CAAATC 75 0.56 
(0.48-0.64) 
0.44 
(0.36-0.52) 
0.40 
(0.30-0.51) 
0.32 
(022-0.43) 
0.28 
(0.19-0.39) 
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Figure 17: Schematic representation of the SNPS with MAF>0.01 in the PXR gene. 
 
The population prevalence of most of the identified SNPs is not documented. Concerning the 
data obtained for SNP -4356 T>C, our population was very similar with the only description 
of this SNP in a Caucasian population (p=0.8814) (Lamba et al., 2008). The prevalence of the 
7635 A>G SNPs in Vietnam is different from all previously described population (appendix1) 
(p=<0.0001-0.01), except for the Asian-American population described by King et al., 2007 
(p=0.1561), the Indian population described by Sandaranaj et al., 2008 (p=0.5684) and the 
Scandinavian population described by Karlsen et al., 2006 (p=0.5612). The frequency of the 
10331 A>G SNP was significantly or near significantly different from all Caucasian 
populations previously described (appendix1) (p=<0.0001-0.0623). Similarities were 
observed with the African-American (p=0.5492) and Asian-American (p=0.5612) population 
described by King et al., 2007. The comparison between our population and the one described 
by Sandaranaj et al. 2008, showed statistically significant differences with the Chinese 
(p=0.0045) and Malay populations (p=0.001), the distribution of this SNPS was similar to the 
one observed in the Indian population (p=0.6622). The same was observed for the 10483 T>C 
SNPs.  Similarities for this SNPs were only observed between the Vietnamese population and 
a previously described Asian-American (p=1.000) population, all other previously described 
population were statistically significantly different (p=<0.001-0.0258) (King et al., 2007) 
(appendix 1).   
The linkage between the SNPs identified was also studied. Using the software Haploview, 
five main linkage disequilibrium blocks were identified in this population:1) -25913 C>T, -
PXR / NR1I2 
3q13-q21 
 
1b 2 3 4 5 6 7 8       9 
281 bp 219 bp 134 bp 
188 bp 275 bp 143 bp 117 bp 106 bp 683 bp 
~24.0 
Kb 
~2.61 
Kb 
~1.34 
Kb 
~0.96 
Kb 
~2.02 
Kb 
~0.20 
Kb 
~0.29 
Kb 
~1.24 
Kb 
5’ 3’ 
Exons 
Introns 
1a 
211 bp 
~0.41 
Kb 
-25385 C>T 
-24910 G>A 
-24381 A>C -23925 C>T 
-23913 T>G 
-14042 C>A 
-4356 T>C 
-601 A>G 
252 A>G 
275 A>G 
308 A>T 
3015 T>G 5761 A>G 
7635 A>G 
7675 C>T 
8055 C>T 
8118 C>T 
8582 T>G 
9683 A>G 
9915 T>A 
9932 C>G 
9976 G>A 
9987 G>A 
10058 C>G 
10098 C>T 
10331 A>G 
10483 T>C 
10719 A>G 
10976 G>A 
11156 A>C 
11193 T>C 
-25913 C>T 
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25385 C>T, -24910 G>A and -24381 A>C; 2) -14042 C>A, -4356 T>C, -601 A>G; 3) 252 
A>G, 275 A>G; 4) 10331A>G, 10483 T>C; 5) 11156 A>C, 11193 T>C (Figure 18). 
Complete LD between the SNPs in block 2 and 3, and the SNP 7675 was also observed. 
These SNP was also found to be in linkage with the SNPs in Block 4 and 5.  The SNPs in 
these blocks were in linkage with the SNP 7635. It was also observed a linkage between the 
SNPs in block 1 and in block 3. In figure 19 it is described the haplotype frequencies based on 
these linkage blocks. 
 
 
Figure 18: Linkage disequilibrium analysis of the PXR SNPS with variant allelic frequency > 0.01.  The 
analysis was performed using haploview. Red squares indicate statistically significant (LOD>2) allelic 
association (linkage disequilibrium, LD) between the pair of SNPs, as measured by the D’ statistic; darker colors 
of red indicate higher values of D’, up to a maximum of 1. White squares indicate pairwise D’ values of <1 with 
no statistically significant evidence of LD. Blue squares indicate pairwise D’ values of 1 but without statistical 
significance. 
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Figure 19: Frequencies of the main haplotypes observed in the Vietnamese population. The analysis was 
performed using haploview. 
 
3.3. ROLE OF PXR SINGLE NUCLEOTIDE POLYMORPHISMS IN THE 
INTER-INDIVIDUAL VARIABILITY OF CYP3A INDUCTION UPON 
TREATMENT WITH BY ARTEMISININ AND ITS DERIVATIVES. 
 
3.3.1. INTER-INDIVIDUAL VARIABILITY IN THE INDUCTION OF 
CYP3A ACTIVITY UPON EXPOSURE TO ARTEMISININ AND ITS 
DERIVATIVES IN A CLINICAL STUDY. 
 
A high inter-individual variability for CYP3A activity induction was observed in the study 
described by Asimus et al., 2007, for the individuals treated with 500 mg/orally artemisinin 
during a 5 day period as described in section 2.2.12.1. The groups of individuals treated with 
other compounds from the artemisinin family, showed lower inter-individual variability and 
CYP3A activity induction (Figure 20). The activity of this family of proteins was previously 
determined by the measurement of the 1-OH-midazolam/midazolam 4 hr plasma 
concentration ratio. This data was kindly provided by Prof. Dr. Michael Aston and Dr. Sarah 
Asimus, Gothenburg University, Sweden. 
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Figure 20: Inter-individual variability in CYP3A activity of Vietnamese individuals treated with different 
artemisinin related compounds. Induction of CYP3A activity was measured as the 3A 1-OH-
midazolam/midazolam 4 hr plasma concentration ratio at day5 normalized to day-6. These pharmacokinetic 
parameters were determined as described by Asimus et al., 2007. 
 
A closer look at the individuals treated with artemisinin showed that the degree of CYP3A 
induction was not dependent on its basal levels, having individuals with the same basal level 
and with the highest (5.07) and lowest (1.19) inductions of CYP3A activity. No correlation 
was observed using a spearman correlation test (Figure 21). 
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Figure 21: Relation between CYP3A activity basal levels and its induction in Vietnamese individuals 
treated with artemisinin. Basal level data corresponds to 3A 1-OH-midazolam/midazolam 4 hr plasma 
concentrationr atio at day-6.  Induction data was obtained by the 3A 1-OH-midazolam/midazolam 4 hr plasma 
concentration ratio at day5 normalized to day-6.These pharmacokinetic parameters were determined as described 
by Asimus et al., 2007. 
 
This led us to study if genetic variability in CYP3A known activator, and main xenosensor 
PXR, was involved in this inter-individual variability. The results of these studies are 
described in the following chapters. 
 
3.3.2. ASSOCIATION BETWEEN PXR GENETIC VARIABILITY AND 
CYP3A ACTIVITY INDUCTION BY ARTEMISINS IN A VIETNAMESE 
POPULATION 
A comparison between the group of individuals with higher (50%) and lower CYP3A (50%) 
activity induction upon exposure to one of the antimalarials aforementioned did not show any 
statistically significant difference between the two groups concerning the genetic variability 
in PXR (data not showed). 
To eliminate the effect of the different treatments, the induction of CYP3A activity for all 
compounds was normalized to the individualas showing the lowest induction in each group. A 
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trend could be observed for the SNPs 252 and 275, the prevalence of individuals homozygous 
for reference allele being higher among the low induction group of individuals (Table 13). 
Table 13: Association between the PXR genotypes and the CYP3A activity induction. For each drug the 
induction were normalizedto the individual showing the lowest induction in each group (green: homozygous for 
the reference allele; orange: heterozygous; red: homozygous for the variant allele; yellow: unknown). The table 
is organized in terms of progressive decrease of induction. ART: artemisinin; ARE: arteether; ARM: 
artemeether; AS: artesunate; DHA: dihydro-artemisinin. 
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ARM 5,62                                                                 
ART 4,24                                                                 
ART 3,12                                                                 
ART 3,11                                                                 
ART 2,97                                                                 
ART 2,91                                                                 
ARE 2,68                                                                 
ARE 2,67                                                                 
ARE 2,57                                                                 
ARE 2,50                                                                 
ARE 2,44                                                                 
ARE 2,42                                                                 
ART 2,38                                                                 
ART 2,31                                                                 
ARE 2,30                                                                 
DHA 2,28                                                                 
AS 2,25                                                                 
AS 2,24                                                                 
ARM 2,21                                                                 
ART 2,19                                                                 
ART 2,05                                                                 
ARM 2,13                                                                 
ART 2,04                                                                 
AS 2,03                                                                 
ARE 1,98                                                                 
ARE 1,95                                                                 
ART 1,91                                                                 
ARE 1,90                                                                 
ARM 1,87                                                                 
ARE 1,72                                                                 
ARM 1,68                                                                 
ARM 1,64                                                                 
AS 1,63                                                                 
ARM 1,62                                                                 
DHA 1,61                                                                 
ARE 1,57                                                                 
ART 1,57                                                                 
AS 1,57                                                                 
ART 1,56                                                                 
ARM 1,54                                                                 
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AS 1,52                                                                 
ARE 1,51                                                                 
DHA 1,49                                                                 
DHA 1,44                                                                 
DHA 1,44                                                                 
AS 1,44                                                                 
ARM 1,43                                                                 
AS 1,43                                                                 
AS 1,40                                                                 
ARM 1,40                                                                 
ARE 1,39                                                                 
DHA 1,39                                                                 
AS 1,38                                                                 
AS 1,38                                                                 
ARM 1,36                                                                 
AS 1,31                                                                 
ARM 1,30                                                                 
DHA 1,27                                                                 
DHA 1,24                                                                 
DHA 1,24                                                                 
ARM 1,24                                                                 
AS 1,21                                                                 
DHA 1,17                                                                 
DHA 1,00                                                                 
ARE 1,00                                                                 
ART 1,00                                                                 
AS 1,00                                                                 
ARM 1,00                                                                 
 
 
A step-wise comparison was performed between subsets of individuals showing high and low 
induction using fisher exact test and are shown in figure 22. A higher frequency of the G 
allele was observed in this subset of individuals, statistical significant differences were 
observed for the SNPs 252 and 275 A>G when comparing the 40% higher inducers with the 
60% lower inducers (p=0.0138). The same was observed until the fractioning of 60% higher 
inducers and 40% lower inducers (p=0.0216).  
Analysis of the 10331 A>G and 10483 T>C also revealed a high prevalence of the 
polymorphic allele the in the fraction of 30 and 40% of high inducers compared with the rest 
of the population (p=0.0490 and 0.0434, respectively). 
Statistically significant differences were also obtained for the stratification of the population 
according to the -601 A>G SNPs, when the 60% higher inducers were compared with the rest 
of the population (p=0.0463). The same was observed for the subset 90%/10% (p=0.0451). 
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Figure 22: Comparison of the genetic diversity of selected SNPs in subgroups of individuals treated with 
artemisinins. The p values represent the comparison between the percentages of high and low inducers. The 
values were obtained using the fisher test. 
 
A special attention was given to the individuals treated with artemisinin in order to assess the 
correlation between PXR SNPs and their high inter-individual variability in induction of 
CYP3A activity (table 14). No association between any of the SNPs and CYP3A induction 
was observed, a fact that might be due to the small number of individuals treated with this 
drug, not allowing significant statistic associations. 
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Table 14: Genotyping data of PXR in Vietnamese individuals treated with 500 mg/orally artemisinin and 
mean CYP3A4 activity induction; 
a 
Position of SNP in GenBank sequence AF364606.1 with +1 being the first 
nucleotide of the start codon (CTG) in exon2 (nucleotide 70390); 
b 
Number of individuals analyzed; 
c
 Value in 
parenthesis is the 95% confidence interval determine by the modified Wald method using GraphPad Quickcalcs 
software; 
d
 Value in parenthesis is the Std. deviation determined using the software GraphPad Prism.  
Position
a
 Aminoacid Identifier n
b
 Genotypic frequencies
c
 Mean CYP3A4
d
 
activity induction 
d
 -25913 C>T  rs1523130 14 C/C 0.57 (0.32- 0.79) 2.76 (±0.83) 
 C/T 0.36 (0.16- 0.61) 2.82 (±1.32) 
 T/T 0.07 (0.00- 0.33) 3.74  
-25385 C>T  rs3814055 14 C/C 0.57 (0.32- 0.79) 2.76 (±0.83) 
 C/T 0.36 (0.16- 0.61) 2.82 (±1.32) 
 T/T 0.07 (0.00- 0.33) 3.74  
-24381 A>C  rs1523127 14 A/A 0.57 (0.32- 0.79) 2.76 (±0.83) 
 A/C 0.36 (0.16- 0.61) 2.82 (±1.32) 
 C/C 0.07 (0.00- 0.33) 3.74  
-23913 T>G   10 T/T 0.50 (0.24- 0.76) 2.56 (±1.13) 
 T/G 0.40 (0.17- 0.69) 3.06 (±0.54) 
 G/G 0.10 (0.00- 0.43) 2.62  
-14042 C>A   14 C/C 0.29 (0.11- 0.55) 2.87 (±0.62) 
 C/A 0.57 (0.32- 0.79) 2.77 (±0.74) 
 A/A 0.14 (0.03- 0.41) 3.13 (±2.74) 
-4356 T>C  rs13059232 14 T/T 0.14 (0.03- 0.41) 3.13 (±2.74) 
 T/C 0.50 (0.27- 0.73) 2.90 (±0.70) 
 C/C 0.36 (0.16- 0.61) 2.67 (±0.70) 
-601 A>G  rs7643645 14 A/A 0.29 (0.11- 0.55) 2.77 (±0.77) 
 A/G 0.57 (0.32- 0.79) 2.82 (±0.68) 
 G/G 0.14 (0.03- 0.41) 3.13 (±2.74) 
252 A>G  rs1464603 14 A/A 0.21 (0.07- 0.48) 2.34 (±1.18) 
 A/G 0.58 (0.32- 0.79) 3.01 (±1.07) 
 G/G 0.21 (0.07- 0.48) 2.93 (±0.70) 
275 A>G  rs144602 14 A/A 0.29 (0.11- 0.55) 3.03 (±1.67) 
 A/G 0.50 (0.27- 0.73) 2.71 (±0.72) 
 G/G 0.21 (0.07- 0.48) 2.93 (±0.70) 
3015 T>G   13 T/T 0.54 (0.29- 0.77) 2.88 (±1.31) 
 T/G 0.31 (0.12- 0.58) 2.94 (±0.55) 
 G/G 0.15 (0.03- 0.43) 3.05 (±0.60) 
7635 A>G  rs6785049 14 A/A 0.07 (0.00- 0.33) 2.28  
 A/G 0.64 (0.39- 0.84) 2.98 (±0.67) 
 G/G 0.29 (0.11- 0.55) 2.69 (±1.69) 
7675 C>T  rs6797879 13 C/C 0.46 (0.23- 0.71) 2.91 (±1.40) 
 C/T 0.54 (0.29- 0.77) 2.80 (±0.69) 
 T/T 0 (0.00- 0.27) - 
8055 C>T  rs2276707 14 C/C 0.58 (0.32- 0.79) 2.76 (±0.67) 
 C/T 0.21 (0.07- 0.48) 3.22 (±0.52) 
 T/T 0.21 (0.07- 0.48) 2.71 (±2.07) 
8118 C>T   13 C/C 0.54 (0.29- 0.77) 3.29 (±0.99) 
 C/T 0.46 (0.23- 0.71) 2.34 (±0.88) 
 T/T 0 (0.00- 0.27) - 
8582 T>G   13 T/T 0.54 (0.29- 0.77) 2.85 (±1.26) 
 T/G 0.46 (0.23- 0.71) 2.95 (±0.74) 
 G/G 0 (0.00- 0.27) - 
9915 T>A F420Y  14 T/T 0.93 (0.67-1.00) 2.98 (±0.90) 
 T/A 0.07 (0.00-0.34) 1.19 (±0.00) 
 A/A 0.00 (0.00-0.25) - 
9932 C>G Q426E  14 C/C 0.93 (0.67-1.00) 2.78 (±1.00) 
 C/G 0.07 (0.00-0.34) 3.72 
 G/G 0.00 (0.00-0.25) - 
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9976 G>A  rs3732358 14 G/G 0.86 (0.59-0.96) 2.96 (±1.02) 
 G/A 0.14 (0.03-0.41) 2.16 (±0.40) 
 A/A 0.00 (0.00-0.25) - 
10058 C>G   14 C/C 0.93 (0.67-1.00) 2.88 (±1.02) 
 C/G 0.07 (0.00-0.34) 2.45  
 G/G 0.00 (0.00-0.25) - 
10331 A>G  rs3732359 14 A/A 0.14 (0.03-0.41) 2.08 (±0.29) 
 A/G 0.29 (0.11-0.55) 3.06 (±0.54) 
 G/G 0.57 (0.33-0.79) 2.94 (±1.21) 
10483 T>C  rs3732360 14 T/T 0.14 (0.03-0.41) 2.08 (±0.29) 
 T/C 0.29 (0.11-0.55) 3.06 (±0.54) 
 C/C 0.57 (0.33-0.79) 2.94 (±1.21) 
10719 A>G  rs6438550 13 A/A 0.62 (0.35-0.82) 2.74 (±1.26) 
 A/G 0.23 (0.07-0.51) 2.61 (±0.16) 
 G/G 0.15 (0.03-0.44) 3.28 (±0.62) 
10976 G>A   14 G/G 0.29 (0.11- 0.55) 2.31 (±1.01) 
 G/A 0.71 (0.45-0.89) 3.07 (±0.94) 
 A/A 0 (0.00- 0.25) - 
11156 A>C  rs3814057 14 A/A 0.50 (0.27- 0.73) 2.62 (±0.58) 
 A/C 0.29 (0.11- 0.55) 3.35 (±0.50) 
 C/C 0.21 (0.07- 0.48) 2.71 (±2.07) 
11193 T>C  rs3814058 14 T/T 0.50 (0.27- 0.73) 2.62 (±0.58) 
 T/C 0.29 (0.11- 0.55) 3.35 (±0.50) 
 C/C 0.21 (0.07- 0.48) 2.71 (±2.07) 
 
 
3.3.3. ASSOCIATION BETWEEN PXR GENETIC VARIABILITY AND 
CYP3A4 INDUCTION BY ARTEMISININ IN HUMAN PRIMARY 
HEPATOCYTES 
 
Taken in consideration the group of individuals treated with artemisinin comprised only 14 
subjects, a further test was performed to assess the association between SNPs in PXR and 
CYP3A4 induction by artemisinin in a larger group of individuals. For this purpose cultures 
of primary human hepatocytes were treated with 100 µM artemisinin, and induction of 
CYP3A4 mRNA expression was measured and associated with PXR genotype (Table 15). 
SNPs with MAF > 0.05 in the first group of patients were analyzed by MALDI-TOF-MS 
(data kindly provided by Dr. Kathrin Klein and Dr. Elke Schaeffler, Dr.Margarete Fischer 
Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany) or by sequencing. 
Although a trend can be observed for -14042 C>A, 252 A>G, 275 A>G, 7635A>G, 10331 
A>G where the induction of CYP3A4 expression is suggested to be decreased in homozygotic 
carriers of the variant allele, particularly when compared with homozygous for the wt allele, 
no statistically significant association was observed between the analyzed SNPs and CYP3A4 
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mRNA expression induction most likely due to the high interindividual variability of 
induction. 
 
Table 15: Genotyping data of human primary hepatocytes treated with 100µM artemisinin and their 
mean CYP3A4 induction; 
a 
Position of SNP in GenBank sequence AF364606.1 with +1 being the first 
nucleotide of the start codon (CTG) in exon2 (nucleotide 70390); 
b 
Number of individuals analyzed; 
c
 Value in 
parenthesis is the 95% confidence interval determine by the modified Wald method using GraphPad Quickcalcs 
software; 
d
 Value in parenthesis is the Std. deviation determined using the software GraphPad Prism.  
Position
a
 Identifier n
b
 Genotypic frequencies
c
 Mean CYP3A4
d 
induction by ART
d
 
-25913 T>C rs1523130 37 
T/T 0.22 (0.11-0.37) 13.73 (±12.73) 
T/C 0.51 (0.36-0.67) 18.58 (±26.59) 
C/C 0.27 (0.15-0.43) 12.58 (±10.93) 
-25385 C>T rs3814055 37 
C/C 0.32 (0.19-0.49) 12.23 (±9.93) 
C/T 0.49 (0.33-0.64) 19.92 (±27.25) 
T/T 0.19 (0.09-0.34) 11.90 (±12.57) 
-24381 A>C rs1523127 37 
A/A 0.32 (0.19-0.49) 12.23 (±9.93) 
A/C 0.49 (0.33-0.64) 19.92 (±27.25) 
C/C 0.19 (0.09-0.34) 11.90 (±12.57) 
-14042 C>A  37 
C/C 0.54 (0.38-0.69) 20.81 (±25.98) 
C/A 0.38 (0.24-0.54) 10.45 (±9.88) 
A/A 0.08 (0.02-0.22) 8.71 (±5.99) 
-4356 T>C rs13059232 37 
T/T 0.11 (0.04-0.25) 17.39 (±14.46) 
T/C 0.46 (0.31-0.62) 9.44 (±11.40) 
C/C 0.43 (0.29-0.59) 22.42 (±27.22) 
-601 A>G rs7643645 37 
A/A 0.41 (0.26-0.56) 16.79 (±19.12) 
A/G 0.35 (0.22-0.51) 16.76 (±27.23) 
G/G 0.24 (0.13-0.40) 13.22 (±11.82) 
252 A>G rs1464603 35 
A/A 0.37 (0.23-0.54) 15.37 (±18.29) 
A/G 0.46 (0.31-0.62) 11.40 (±10.09) 
G/G 0.17 (0.08-0.33) 8.48 (±4.22) 
275 A>G rs144602 35 
A/A 0.37 (0.23-0.54) 15.37 (±18.29) 
A/G 0.46 (0.31-0.62) 11.40 (±10.09) 
G/G 0.17 (0.08-0.33) 8.48 (±4.22) 
7635 A>G rs6785049 37 
A/A 0.24 (0.13-0.40) 16.63 (±21.33) 
A/G 0.60 (0.43-0.74) 17.64 (±23.02) 
G/G 0.16 (0.07-0.31) 8.47 (±3.039) 
8055 C>T rs2276707 37 
C/C 0.54 (0.38-0.69) 16.18 (±18.27) 
C/T 0.41 (0.26-0.56) 16.25 (±25.10) 
T/T 0.05 (0.01-0.19) 10.62 (±0.14) 
10331 A>G rs3732359 37 
A/A 0.43 (0.29-0.59) 18.45 (±19.76) 
A/G 0.46 (0.31- 0.62) 15.26 (±23.73) 
G/G 0.11 (0.04- 0.25) 8.57 (±3.56) 
11156 A>C rs3814057 37 
A/A 0.54 (0.38- 0.69) 16.18 (±18.27) 
A/C 0.41 (0.26- 0.56) 16.25 (±25.10) 
C/C 0.05 (0.01- 0.19) 10.62 (±0.14) 
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4. DISCUSSION 
 
4.1. STUDY OF THE CAPACITY OF CURRENTLY USED ANTIMALARIAL 
DRUGS TO ACTIVATE THE PXR/CAR XENOBIOTIC SIGNAL 
TRANSDUCTION SIGNAL. 
 
This study confirms the previously described data concerning the activation of PXR by 
artemether and arteether, and the activation of PXR and CAR by artemisinin (Burk et al., 
2005; Simmonson et al., 2006).  However the EC50 value obtained in this study for the 
induction of PXR by artemisinin is 20µM higher (53.64 µM vs. 34µM) compared to the value 
obtained by Burk and colleagues. This may be due to the different cell lines used, the 
previously described EC50 was obtained performing the gene reporter assay in LS174T cells, 
and in this study the assay was performed in COS1 cells. This difference in values may be an 
indication of a different permeability of the cells for this drug. Comparatively the values 
obtained for the half maximal effective concentration for artemisinin and derivatives were 
higher for the activation of CAR compared with the values obtained for the activation of 
PXR, except for artemether (EC50(CAR)=12.44µM; EC50 (PXR)= 14.15µM).  This may 
indicate preferential activation of PXR as compared to CAR by most artemisinins. 
Due to its short half live and absorption through the liver, it is to expect a higher 
concentration of artemisinin in the liver, comparatively with its systemic plasma 
concentration. Together with artemisinin, also its metabolite deoxy-artemisinin was also 
identified as a ligand for PXR and CAR, in cellular assays, and further induced CYP3A4 and 
CYP2B6 in the hepatocytes. Taken in consideration this fact, the induction of CYP3A activity 
observed in vivo by artemisinin in the Asimus study, may result from the combined action of 
artemisinin and its metabolite in the cells. 
Together with these compounds also DHA was studied in human hepatocytes. No data was 
obtained from the cellular assays due to the high toxicity of this compound, however this 
characteristic was not observed in human primary hepatocytes. This may be due to the 
presence of drug metabolizing enzymes and transporters in the hepatocytes, helping to 
eliminate DHA, thereby reducing its intra-cellular availability and consequent toxicity. This 
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conversion is mediated by UGT1A6 and UGT2B7 (Kerb et al., 2009). A repression of the 
expression of CYP3A4 and CYP2B6 was observed in the human hepatocytes, however this 
was not corroborated with the data from the clinical study performed in Vietnam, where a 
slight induction of CYP3A activity was observed (Asimus et al., 2007). This may be the result 
of the action of other compounds on PXR in vivo. 
Another member of this family of compounds, artesunate, also repressed the induction of 
CYP3A4 and CYP2B6 in human hepatocytes. But contrary to the previously described 
compound, for artesunate, data from in vitro assays is available, and corroborates the 
repression observed in human hepatocytes.  
Taken together the in vitro data obtained from this study with the in vivo data obtained from 
the only clinical study involving artemisinin and cytochrome P450 induction (Asimus et al., 
2007), the high induction observed by artemisinin, as compared to artemether and arteether, 
may result from the combined action of the parent drug and its metabolite deoxy-artemisinin 
in the hepatocytes. Not happening with the other compounds, as these are metabolized to 
DHA, a compound that in human hepatocytes showed a repression of CYP3A mRNA 
expression and thus may counteract the induction of the parent compounds. 
Together with these compounds, also, amodiaquine induced simultaneously PXR and CAR. 
However, no induction was observed in human hepatocytes, and even a repression of 
CYP3A4 was observed. This may be partially explained by its toxicity and disruption of the 
normal cell machinery, but is also an indication that although the drug may have the capacity 
to induce the interaction of the nuclear receptor with its co-activator; it may not be able to 
induce the release of co-repressor. This was previously observed for docetaxel, which was 
showed to promote the interaction of PXR with its coactivators, however did not activate this 
nuclear receptor. This was associated with a failure to disrupt to interaction of PXR with its 
co repressors (Synould et al., 2001). Further tests, e.g., co-repressor release assay, are 
necessary to confirm this hypothesis.  
This work also provides the first evidences for activation/ligand binding of PXR by the 
quinoline antimalarials lumefantrine, carboximefloquine, DEAQ and chloroquine, in a 
mammalian two hybrid assay. From these compounds only carboximefloquine was observed 
to induce CYP2B6 in the hepatocytes culture, confirming the data obtained in the cellular 
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assay (table 16). This suggests a gene specific effect of this drug, since no induction was 
observed for CYP3A4, and MDR1. This compound is formed, from the parent antimalarial 
mefloquine, by the action of CYP3A4 (Fontaine et al., 2000). No data is available regarding 
the plasma concentration of carboxymefloquine in patients, but considering the plasma 
concentrations observed for mefloquine ranging from 2.500ng/ml-2.830ng/ml depending on 
the drug supplier (Gutman et al., 2009), and its long half time (14-15 days), we may expect 
that high concentrations of this metabolite may be reachable in the patients liver, increasing 
their probability of drug interactions due to the induction of the PXR system 
Lumefantrine and chloroquine did not show any induction in human primary hepatocytes. 
This observation may result from the influence of the high amount of Me2SO, 0.8% compared 
with the normal 0.1% regularly used for the other compounds. This was also observed in the 
induction control rifampicin; when usend with 0.1% Me2SO its mean induction of CYP3A4 
was 2.5x higher compared with the treatment containing 0.8% Me2SO (Figure 14). This was 
due to a higher basal level of the measured genes in the presence of a high amount of Me2SO, 
and consequent lower induction. Another factor that has to be taken in consideration to 
explain this data is the uptake transport of these drugs, no data is available at the moment 
about this mechanism. A further test that should be performed with these compounds should 
be the measurement of its concentrations in the hepatocytes, to confirm that the uptake of the 
drugs is occurring, and exclude the possibility that the non-induction is resulting from the low 
concentration of compounds inside the cell. No quantifiable value for the maximum induction 
for lumefantrine was obtained, due to the fact that the plateau phase was not reached. 
Nevertheless, the in vitro induction data obtained for this drug is of particular interest due to 
its long high half life time (up to 6 days) and common utilization in malaria therapeutics; 
combined with artemeether (Coartem
®
) it is the most prevalent first line treatment in the 
world (WHO, 2010). The in vitro induction of PXR is an indication that lumefantrine may 
suffer also from auto-induction of its detoxification, since CYP3A4/5 are the main enzymes 
involved in this process and known targets for PXR. This is of concern if the concentration 
necessary to activate PXR is lower than the maximum concentration in the liver. No data is 
available regarding the concentration of this drug in the liver, however its plasma 
concentration is described as being 6.757 ng/ml (Mwesigwa et al., 2010). Further tests are 
necessary to determine the correct concentration necessary to induce the PXR system. 
Together with malaria, a high incidence of HIV and TB co-exists in the same regions(WHO, 
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2010) making patients treated with lumefantrine more prone to develop drug-drug interactions 
in the case of drugs metabolized by enzymes regulated by PXR.  
Amodiaquine and its active metabolite DEAQ activate PXR with EC50’s of, respectively, 
17.20µM (7.99 mg/ml) and ~24.74 µM (8.11mg/ml). These values are much higher than the 
observed maximum plasma concentration observed for amodiaquine (5.2ng/ml) and DEAQ 
(253ng/ml) (Mwesigwa et al., 2010). However liver concentrations of these compounds may 
be much higher than plasma concentrations, as so, concern should be taken in the future, if a 
dosage increase is necessary, and preliminary tests to assess the intra-hepatic concentration of 
these compounds should be performed. 
 
Table 16: Compilation of the results concerning the capacity of currently used antimalarials to activate 
the PXR/CAR system obtained during this project. 
   Human Hepatocytes  
Drug 
Nuclear 
Receptor 
In vitro 
induction 
Induction Repression In vivo 
Artemisinin PXR/CAR  
CYP3A, CYP2B6 
and MDR1 - 
CYP3A activity 
induction 
Arteether PXR/CAR  
CYP3A4, CYP2B6 
and MDR1 - 
CYP3A activity 
induction 
Artemether PXR/CAR  
CYP3A4 and 
CYP2B6  - 
CYP3A activity 
induction 
Deoxy-arteether PXR/CAR  
CYP3A4 and 
CYP2B6 - - 
Deoxy-artemisinin PXR/CAR  
CYP3A4 and 
CYP2B6 - - 
DHA - - 
- 
CYP3A4 and 
CYP2B6 
CYP3A activity 
induction 
Artesunate PXR/CAR repression 
- CYP3A4 and 
CYP2B6 
CYP3A activity 
induction 
Lumefantrine PXR  - - - 
Carboximefloquine PXR  CYP2B6 - - 
DEAQ PXR  
 CYP3A4 and 
CYP2B6 - 
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Chloroquine PXR  - - - 
Amodiaquine PXR/CAR  - CYP3A4 - 
 
A further methodological approach was used to confirm the interaction of the aforementioned 
compounds with CAR. A C.A.R.L.A. assay was chosen for this purpose, but due to low 
sensitivity no induction was observed for these compounds at the same concentrations used in 
the hepatocytes, except for arteether (Figure 17). Due to this observation, only one experiment 
was performed. 
In mammalian two hybrid experiments, only the activation of CAR by ligand binding of the 
compounds was studied. Further studies are necessary to identify the compounds that act as 
CAR activators by inducing its translocation to the nucleus. One known compound that acts 
by this particular mechanism is phenobarbital (Kodama and Negishi, 2006). Taken this in 
consideration we cannot exclude completely the hypothesis that one of the other antimalarials 
may act in the same way as phenobarbital, as so, we may only state that the compounds 
identified in this study induce the CAR system, but we cannot conclude anything about the 
compounds not positive in our experiments. The translocation of CAR could be studied using, 
e.g., yellow fluorescent protein-tagged-human constitutive androstane receptor, by the direct 
observation of the translocation of CAR to the nucleus (Li et al., 2009). 
  
4.2. STUDY OF THE GENETIC VARIABILITY IN PXR IN A VIETNAMESE 
POPULATION  
 
To the best of our our knowledge, this is the first extensive description of PXR genetic 
variability in a Southeast Asian population, being actually the first study re-sequencing of  
this gene after the first publication describing its genetic variability almost one decade ago 
(Hustert et al., 2001; Zhang et al., 2001). The re-sequencing technique chosen in this project, 
revealed to be an appropriate approach, which, complemented with the use of MALDI-TOF-
MS, allowed the analysis of 79 positions of genetic variability, six of them not described 
previously. All SNPs were in Hardy-Weinberg equilibrium, except the PXR 8055C>T and 
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10976 G>A SNP. This anomaly may be either due to not sufficiently isolated populations, or 
just a reflection of the small group of samples analyzed, since the hypothesis of 
methodological error during the determination of this genotype was discarded by the use of 
two independent genotyping methods, re-sequencing and MALDI-TOF-MS (data kindly 
provided by Dr. Elke Schaeffler, Dr.Margarete Fischer-Bosch- Intitute of 
ClinicalPharmacology, Stuttgart, Germany). 
The gene was highly conserved in this population (from the 79 SNP positions studied, only 32 
could be identified). Only 4 SNPs in the ORF of the gene were observed. Being the 
synonymous SNP 8118C>T the most prevalent (MAF=0.26), the other 3 non-synonymous 
SNPs were only found in the heterozygous form in 1-2 individuals. The newly identified SNP 
9915 T>A (F240Y) is localized in exon9, in the region encoding the LBD of the protein; as 
so, it may be hypothesized that this SNP may influence ligand binding. This was confirmed 
by molecular docking studies that revealed a disruption of ligand binding in the presence of 
the tyrosine (Y) (data kindly provided by Pedro Ferreira, Department of Medicine, Karolinska 
Institutet, Stockholm, Sweden). 
All other both new as well as previously described SNPs observed in this study, are localized 
in intronic and promoter regions, as well as in the 3’UTR region. The lack of genetic diversity 
in the protein coding sequences suggests that the stability of the protein sequence is essential 
for its function, being kept free of genetic variability during evolution. This is corroborated by 
previously published data (see appendix 1). 
Four hundred and fourteen SNPs are described for this gene 
(http://www.ncbi.nlm.nih.gov/sites/entrez, accessed on 17 May 2010), but only for a few of 
them there is data available regarding their prevalence in other populations. From the data 
available, it is possible to observe that the Vietnamese population shows more similarities to 
an Indian and Asian-American populations then to Caucasians populations (see section 3.2), 
as expected. Surprisingly statistically significant differences were observed for the 10331 and 
10483 SNP, between our population and a Chinese and Malay population. It should be 
expected a higher similarity between the Vietnamese population and the Chinese population, 
due to the fact that Vietnamese are mainly derived from individuals from southern Chinese 
and Thai-Indonesian populations (Ivanova et al., 1999).  One possible explanation is the 
unknown origin of the Chinese population that could be originated in more northern parts of 
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China, and being more diverse to the southern population, and not influencing the Vietnamese 
population. 
 
4.3. ROLE OF PXR SINGLE NUCLEOTIDE POLYMORPHISMS IN THE 
INTER-INDIVIDUAL VARIABILITY OF CYP3A INDUCTION UPON 
TREATMENT WITH BY ARTEMISININ AND ITS DERIVATIVES  
 
This study was based on a previously described clinical study, involving 75 Vietnamese 
individuals treated with 5 different compounds of the artemisinin family (arteether, 
artemeether, artemisinin, artesunate and dihydro-artemisinin). From this study we could see a 
high variability in induction of CYP3A activity, particularly for artemisinin. This compound 
demonstrated the highest induction of CYP3A activity, thereby corroborating the results we 
obtained in vitro (section 3.1.1.). Artemisinin shows the highest induction capacity of all 
compounds of this family of drugs in the PXR system.  This variability was not correlated 
with the basal CYP3A activity, being only visible upon induction with artemisinin (figure 21). 
Altogether, this led us to hypothesize that the observed variability in CYP3A induction was a 
result of genetic variability in its main genetical regulator, PXR.  
In order to normalize induction values for each drug, the data from the induction of each 
individual was normalized to the individual showing the lowest induction in the respective 
group.  An increased prevalence of the 252G and 275G alleles was observed in the group of 
high inducers. No data is available concerning the in vivo effect of the aforementioned SNPs. 
To confirm if the higher CYP3A activity was correlated with the induction of expression of 
its mRNA, further induction studies were performed in human hepatocytes. Contrary to 
expected we observed a higher CYP3A4 mRNA content for the homozygous for the wt allele 
(A/A) comparatively with the homozygous for the variant allele (G/G).  This is an indication 
that the influence of this SNPs does not came directly from the induction of mRNA 
expression. It has to be taken in consideration also, that these are intronic SNPs.  
The newly identified SNP 9915 T>A (F420Y) is located in the ligand binding domain of the 
nuclear receptor. Docking studies revealed a disruption of ligand binding in the presence of 
the amino acid tyrosine (data kindly provided by Pedro Ferreira, Department of medicine, 
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Karolinska Institutet, Stockholm, Sweden). The data was obtained for the ligands rifampicin 
and colupulone. Our experimental data supports this result - the individual carrying this SNP 
showed no induction (1.02) in the group of individuals treated with artemisinin. Further 
studies are necessary to confirm the phenotypic outcome of this SNP, namely directed 
mutagenesis of this aminoacid in the PXR protein coupled with gene reporter assays.  
Also for the SNPs 10331 A>G and 10483 T>C, it was observed a high prevalence of variant 
allele carriers in the high inducers group. A similar association was also previously reported 
by Oleson et al., 2009. Their work showed that individuals that carried these two linked 
polymorphic alleles had 80% higher oral midazolam clearence, an indication of higher 
CYP3A activity. However further analysis in human primary hepatocytes treated with 
artemisinin, showed an opposite trend for SNP 10331, the association between the presence of 
this SNP and CYP3A4 mRNA induction was quite the opposite in the hepatocytes, an increase 
of the induction of CYP3A4 mRNA was observed in the carriers of the wt allele. However the 
statistical analysis of the human hepatocyte data is hampered by the high interindividual 
variability in induction, probably due to diverse origins and quality of the cells. Also the 
underlying pathologies of the patients may also be influencing CYP4A4 induction response to 
these compounds. This may also be an indication that the phenotypic effect from this SNP 
may come from the association with other genetical factors, not only the aforementioned 
SNPs together. 
Our hepatocyte treatment data regarding the polymorphism -14042C>A, could confirm the 
trend described previously by Lamba et al., 2008, were the presence of the polymorphism 
decreases CYP3A4 induction. This was also observed in our hepatocyte data, however no 
association was observed in vivo upon treatment with artemisinin. 
The SNP -601 A>G, was previously reported as being associated with a lower CYP3A4 
activity and lower CYP3A4 mRNA levels. We could observe a decrease in the induction of 
the mRNA levels in the hepatocytes, but could not confirm the decrease in CYP3A4 activity 
in the clinical study. We actually observe a slight increase in its activity upon treatment with 
artemisinin. This may also be explained by the other non-genetical factors influencing 
genetical expression, e.g.  food, environmental pollutants. 
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Our data could not confirm the previously described report on the 7635A/G allele (Zhang et 
al., 2001). We could not observe an increase of CYP3A4 induction in the carries of the G/G 
allele, as reported previously, neither in the clinical study nor in the hepatocytes treatment 
experiment.  
Also to highlight is the presence of the SNPs 9863 A>G (I403V) and 9932 C>G (Q426E) in 
the individual with the lowest induction for the treatment with artesunate. This non-induction 
may come directly from the I403V polymorphism, since this was previously described to 
reduce ligand dependent transactivation of CYP3A4 (Koyano et al., 2002 and 2004). It seems 
that our data confirms the previously described phenotypic association. For the other 
polymorphism no phenotypic association is known, since it has not been studied in this 
context. 
Although some of these results are suggestive of an influence of these specific alleles in the in 
vivo induction capacity of their carriers, one should be cautious when interpreting the data. 
The main overall observation of this analysis is that actually the final phenotype might be the 
result of many small SNP influences. The determination of the precise influence of each one 
awaits further specifically designed studies. 
Taken together we could confirm some of the data published concerning phenotypic changes 
induced by PXR SNPs. However no clear results were obtained for the newly identified SNPs 
due to a limited number of samples, except for the SNP F420Y. 
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APPENDIX1: DESCRIPTION OF THE POLYMORPHISM DESCRIBED IN PUBLICATIONS IN PXR, UNTIL THE PRESENT 
MOMENT  
 
Allele SNP Position in the 
Sequence AF364606 
(GeneBank) (Position 
+1, translatiom 
starting site) 
Rs 
numbering 
Position 
in the 
gene 
effect Functional 
consequence 
Population studied and 
allelic frequency 
Reference  
 -33045 G>A  upstream   C=0.01 Lamba et al. 2008 
 -32911 T>C  upstream   PDR=0.10 Lamba et al. 2008 
 -31539 G>A  upstream   PDR=0.02 Lamba et al. 2008 
 -31408 G>A r4688036 upstream   PDR=0.08 Lamba et al. 2008 
 -31333 G>A  upstream   PDR=0.04 Lamba et al. 2008 
 -31273 A>G r9832958 upsteram   PDR=0.22 Lamba et al. 2008 
 -26966 C>T  upstream   AA=0.16, C=0.00, AS=0.00 King et al. 2007 
 -26612 T>C rs4688038 upstream   AA=0.43, C=0.00, AS=0.00 King et al. 2007 
 -26479 T>C rs9813490 upstream   AA=0.03, C=0.00, AS=0.00 King et al. 2007 
 -26405 C>T rs4687883 upstream   AA=0.06, C=0.00, AS=0.00 King et al. 2007 
 -25913 T>C rs1523130 upstream STAT1, 3, 6, NFAT 
sites lost in Tallele 
Increase Basal CYP3A4, and 
decrease in its induction in 
hepatocytes 
AA=0.28, C=0.70, AS=0.67; 
PDR=0.45, C=0.27; 
C=0.55 
King et al. 2007; 
Lamba et al. 2008; 
Siccardi  et al. 2008 
 -25812 G>A rs1523129 upstream   AA=0.16, C=0.00, AS=0.01; 
PDR=0.06 
King et al. 2007; 
Lamba et al. 2008 
 -25726 C>A     PDR=0.02 Lamba et al. 2008 
 -25564 G>A   upstream HSTF COMP1  C=0.01, AA=0.09 ;  
IE=0.018(IBD), IE=0.030 (Controls); 
C*=0.03 
Zhang et al. 2001;  
 Dring et al. 2006; 
 Bosch et al. 2006 
 -25385 C>T rs3814055 upstream NFKB, ISGF-3 Rif induced ERMBT and fold 
induction after rif: TT>CC; 
Frequency of the minor allele is 
decreased in IBD; Decrease of 
PXR mRNA in males 
C=0.39, AA=0.32;  
IE=0.321 (IBD), IE=0.433 (Controls); 
C*=0.36; 
AA=0.34; C=0.50; AS=0.21; 
ES=0.38 
PDR=0.29, C=0.31; 
CN=0.17; MY=0.21; IN=0.33; 
FR*=0.40 
C=0.405, C(IBD)=0.356; 
ES=0.41 
AR=0.39 
Zhang et al. 2001;  
Dring et al. 2006; 
Bosch et al. 2006; 
King et al. 2007; 
Martinez et al. 2007; 
Lamba et al. 2008; 
Sandanaraj et al. 2008; 
Khaled et al. 2009; 
Lacher et al. 2009; 
Oliver et al. 2010; 
Sookian et al. 2010 
 -25048 C>G rs12721614 upstream   C=0.01, AA=0.00; C*=0.00 Zhang et al. 2001; 
Bosch et al. 2006 
 -25036 G>C  5’UTR   PDR=0.02 Lamba et al. 2008 
  
 
 -25003 C>T  Upstream 
(5’UTR) 
  PDR=0.02 Lamba et al. 2008 
 -24755 C>T     AA=0.02, C=0.00, AS=0.00 King et al. 2007 
 -24756 G>A  rs1523128 upstream C/EBP, HNF1  C=0.01, AA=0.14; 
IE= 0.003(IBD), IE=0.004 (Controls); 
C*=0.01 
AA=0.13, C=0.00, AS=0.00: 
PDR=0.08 
Zhang et al. 2001; 
 Dring et al. 2006; 
Bosch et al. 2006; 
King et al. 2007; 
Lamba et al. 2008 
 -24737
 
A>G   upstream  GBF  C=0.01, AA=0;  
C*=0.005 
Zhang et al. 2001; 
Bosch et al. 2006 
 -24719 C>G   upstream  PR  C=0.01, AA=0;  
C*=0.00 
Zhang et al. 2001; 
Bosch et al. 2006 
 -24586 T>C  upstream   C=0.01, AA=0; 
C*=0.00 
Zhang et al. 2001; 
Bosch et al. 2006 
 -24462G>A  5’UTR   C=0.01, AA=0;  
C*=0.00 
Zhang et al. 2001; 
Bosch et al. 2006 
 -24381 A>C rs1523127 5’UTR  Frequency of the minor allele is 
decreased in IBD; No association 
with UC, CD, or IBD; Associated 
with ABCB1 and CYP3A4 mRNA 
expression in colon tumor.  
C=0.41, AA=0.73; 
IE=0.357(IBD), IE=0.452(Controls); 
C*=0.54; 
SF=0 
AA=0.50, C=0.69, AS=0.33; 
SG*=0.26; 
CA= 
CN=0.26, MY=0.13, IN=0.57; 
CN=0.17, MY=0.26, IN=0.35 
Zhang et al. 2001;  
Dring et al. 2006; 
Bosch et al. 2006;  
Ho et al. 2006; 
King et al. 2007; 
Tham et al. 2007; 
Amre et al. 2008; 
Hor et al. 2008* 
Sandaranaj et al. 2008 
 -24113 G>A  rs2276706 Intron1  Rif induced ERMBT and fold 
induction 
after rif: AA>GG 
C=0.39, AA=0.32 
AA=0.32, C=0.41, AS=0.28; 
CN=0.18, MY=0.23, IN=0.32 
Zhang et al. 2001;  
King et al. 2007; 
Sandaranaj et al. 2008 
PAR.2*2 -24020 6bp del rs3842689 5’UTR HNF1 site lost with 
deletion 
Complete loss of PAR2 promoter 
activity in HepG2 cells 
J= 0.27;  
SK=0.40; 
C=0.29 (D) 
Uno et al. 2003; 
Karlsen et al. 2006; 
Lamba et al. 2008; 
 -23839 Cins rs11421631 5’UTR C insertion present 
in SRE site 
 C=0.26(6C) Lamba et al. 2008 
 -23700 C>T     J=0.024 Koyano et al. 2002 
 -23350C> rs12488820    AR=0.42 Sookian et al. 2010 
 -22373 C>T rs2472671    AR=0.14 Sookian et al. 2010 
 -20349 A>T rs4234666 Intron1   PDR=0.09 Lamba et al. 2008 
 -20102 G>C  Intron1   PDR=0.23 Lamba et al. 2008 
 -19744 C>T r4472074 Intron1   PDR=0.08 Lamba et al. 2008 
 -19724 A>G  Intron1   PDR=0.23 Lamba et al. 2008 
 -19715 insC r11409387 Intron1   PDR=0.23 (n) Lamba et al. 2008 
 -19118 A>G  Intron1   PDR=0.02 Lamba et al. 2008 
 -19043 C>A  Intron1   PDR=0.02 Lamba et al. 2008 
 -18835 del r3030845 Intron1   PDR=0.26 (n) Lamba et al. 2008 
 -18500 G>T  Intron1   PDR=0.05 Lamba et al. 2008 
 -18445 (TTA ins)  Intron1   PDR=0.10 (TTA/5) Lamba et al. 2008 
 -18433 C>A  Intron1 Repeat is present in 
FOXJ2 site 
 PDR=0.02 Lamba et al. 2008 
 -18432 G>A  Intron1   PDR=0.02 Lamba et al. 2008 
  
 
 -18334 C>A  Intron1   PDR=0.02 Lamba et al. 2008 
 -17910 C>T  Intron1   PDR=0.02 Lamba et al. 2008 
 -17889 C>T r4566573 Intron1 SNP present in DR4 
site 
 PDR=0.02 Lamba et al. 2008 
 -17785 T>C  Intron1   C=0.03 Lamba et al. 2008 
 -14974 A>G  Intron1   PDR=0.10, C=0.99 Lamba et al. 2008 
 -14882 C>T  Intron1   C=0.01 Lamba et al. 2008 
 -14555 T>C  Intron1 PPAR  site gained 
in C allele 
 C=0.01 Lamba et al. 2008 
 -14479 T>A  Intron1   C=0.02 Lamba et al. 2008 
 -14438 G>C  Intron1 SNP present in DR4 
site 
 PDR=0.04, C=0.02 Lamba et al. 2008 
 -14260 C>G  Intron1   C=0.01 Lamba et al. 2008 
 -14165 G>C  Intron1   PDR=0.02, C=0.00 Lamba et al. 2008 
 -14080 T>G  Intron1   C=0.01 Lamba et al. 2008 
 -14042 C>A  Intron1 SNP present in DR3 
site 
Increase basal CYP3A4 and 
decrease in its fold induction 
PDR=0.44, C=0.29 Lamba et al. 2008 
 -13451 A>G  Intron1   PDR=0.02 Lamba et al. 2008 
 -13389 C>T  Intron1   PDR=0.02 Lamba et al. 2008 
 -13354 C>G  Intron1   PDR=0.08 Lamba et al. 2008 
 -13043 C>T  Intron1   PDR=0.04 Lamba et al. 2008 
 -12838 G>A  Intron1   PDR=0.08, C=0.02 Lamba et al. 2008 
 -12780 C>G  Intron1   PDR=0.02 Lamba et al. 2008 
 -12665 T>C  Intron1   PDR=0.02 Lamba et al. 2008 
 -12585 A>G rs6773295 Intron1   PDR=0.10, C=0.02 Lamba et al. 2008 
 -12565 G>T rs6438545 Intron1   PDR=0.10, C=0.02 Lamba et al. 2008 
 -12554 A>T  Intron1   PDR=0.02 Lamba et al. 2008 
 -12285 T>G  Intron1   C=0.01 Lamba et al. 2008 
 -12202 T>C rs13085558 Intron1  Increase in basal CYP3A4 activity 
and decrease in its inducibility 
PDR=0.10, C=0.09 Lamba et al. 2008 
 -12156 G>A  Intron1   PDR=0.04 Lamba et al. 2008 
 -11752 G>A  Intron1   PDR=0.08, C=0.03 Lamba et al. 2008 
 -11540 A>T  Intron1 HNF4 site lost in T 
allele 
 PDR=0.06 Lamba et al. 2008 
 -11443 G>A  Intron1   PDR=0.02, C=0.01 Lamba et al. 2008 
 -11413 C>T  Intron1   PDR=0.28 Lamba et al. 2008 
 -11381 G>T  Intron1   PDR=0.36 Lamba et al. 2008 
 -9513 T>C  Intron1 HEB site gained in 
C allele 
 PDR=0.21, C=0.03 Lamba et al. 2008 
 -7945 G>A  Intron1 SNP present in 
HNF4  and NF1 
sites 
 PDR=0.09, C=0.02 Lamba et al. 2008 
 -7941 A>G  Intron1 SNP present in NF1 
site 
 PDR=0.09, C=0.02 Lamba et al. 2008 
 -7938 A>T  Intron1 SNP present in NF1 
site 
 PDR=0.09, C=0.02 Lamba et al. 2008 
 -7930 C>A  Intron1   PDR=0.09, C=0.02 Lamba et al. 2008 
 -7924 A>G  Intron1   PDR=0.17, C=0.04 Lamba et al. 2008 
  
 
 -7923 A>G  Intron1   PDR=0.09, C=0.02 Lamba et al. 2008 
 -6994 C>T rs2472677 Intron1 SNP present in 
HNF3  site 
Increases CYP3A4 activity and 
decrease in its fold induction; 
Increase in PAR2 and PXR 
mRNA; Correlated with reduced 
concentrations of atazanavir 
PDR=0.35, C=0.62; 
C=0.66 
Lamba et al. 2008; 
Siccardi et al. 2008 
 -6942 C>A  Intron1   C=0.01 Lamba et al. 2008 
 -6827 T>G  Intron1   PDR=0.06 Lamba et al. 2008 
 -6686 A>G rs12492296 Intron1   PDR=0.35, C=0.62 Lamba et al. 2008 
 -6577(CAAA)5/6. (CA) 12/14 rs4267673, 
rs7372335 
Intron1 HNF3  site gained 
by (CAAA)CA 
insertion 
 PDR= 0.42 (6/13), C=0.38 (6/12) Lamba et al. 2008 
 -6513 T>C rs6438546 Intron1   PDR=0.36, C=0.37 Lamba et al. 2008 
 -5286 T>C   rs2461823    SF=0.62; 
AR=0.44 
Ho et al. 2006 
Sookian et al. 2010 
 -4356 T>C rs13059232 Intron1   PDR=0.44, C=0.65 Lamba et al. 2008 
 -4129 G>A  Intron1   PDR=0.041 Lamba et al. 2008 
 -2228 G>T rs2416818 Intron1   PDR=0.12 Lamba et al. 2008 
 -2009 G>T rs4688040 Intron1 SNP present in 
HNF3  site 
 PDR=0.46, C=0.21 Lamba et al. 2008 
 -1934 G>T  Intron1   C=0.20 Lamba et al. 2008 
 -1855 G>A  Intron1   PDR=0.40 Lamba et al. 2008 
 -1797 T>G  Intron1   PDR=0.02 Lamba et al. 2008 
 -1772 T>C  Intron1 DR4 site lost in C 
allele 
 PDR=0.02 Lamba et al. 2008 
 -1683G>A rs4688041 Intron1   PDR=0.08 Lamba et al. 2008 
 -1650 T>A rs2472679 Intron1  Decrease in basal CYP3A4 and 
increase in its inducibility 
PDR=0.08, C=0.04 Lamba et al. 2008 
 -1586 C>T  Intron1   PDR=0.02 Lamba et al. 2008 
 -1495 C>A  Intron1   PDR=0.02 Lamba et al. 2008 
 -1447 C>A rs2461817 Intron1 SNP present in DR3 
and C/EBP  sites 
 PDR=0.35, C=0.25 Lamba et al. 2008 
 -1145 C>T  Intron1 CREB site lost in T 
allele 
 C=0.05 Lamba et al. 2008 
 -977 G>A  Intron1   PDR=0.02 Lamba et al. 2008 
 -902 A>G  Intron1   PDR=0.04, C=0.05 Lamba et al. 2008 
 -626 G>T  Intron1   PDR=0.13, C=0.36 Lamba et al. 2008 
 -601 A>G rs7643645 Intron1 HNF4 site lost in G 
allele 
Decreased CYP3A4 actiity and 
increase in its fold induction. 
Decrease in MDR, 3A4 and PXR 
mRNA 
SF=0.37; 
PDR=0.55, C=0.36; 
C=0.37; 
AR=0.47 
Ho et al. 2006; 
Lamba et al. 2008; 
Siccardi et al. 2008; 
Sookian et al. 2010; 
 -114G>A  Intron1   J=0.0024 Koyano et al. 2002 
 -40T>C  Intron1   C=0.00, AA=0.05;  
C*=0.00 
Zhang et al. 2001; 
Bosch et al. 2006 
 -42T>C rs12721597 Intron1   C=0.00, AA=0.23; 
AA=0.10, C=0.00, AS=0.063  
Zhang et al. 2001;  
King et al. 2007 
 23 G>C   S8T  AA=0.03, C=0.00, AS=0.00 King et al. 2007 
PXR*9 52 G>A   Exon2 E18K same as WT in transactivation C=0.0, AA=0.014;  Husert et al. 2001; 
  
 
assays, basal and rif and 
corticosterone activation 
C*=0.00; 
CN=0.00; 
ZZ=0.00 
Bosch et al. 2006; 
Wang et al. 2008; 
Ferreira et al. 2008 
PXR*2 79 C>T  rs12727613 Exon2 P27S, DBD Hepatic CYP3A4 not different. C=0.0, AA=0.20 ; 
C=0.0, AA=0.15; 
C*=0.00; 
AA=0.03, C=0.00, AS=0.00; 
C(ICP)=0.006; 
CN=0.00; 
ZZ=0.112 
Zhang et al. 2001;  
Hustert et al. 2001; 
Bosch et al. 2006;  
King et al. 2007; 
Owen et al. 2008;  
Wang et al. 2008; 
Ferreira et al. 2008 
PXR*3 106 G>A   Exon2 G36R, DBD same as WT in transactivation 
assays for basal and 
rif but 40 % increase with 
corticosterone (Hustert et al. 2001) 
C=0.01, AA=0.03;  
C=0.03, AA=0.0;  
IE=0.016(IBD), IE=0.031(Controls); 
C*=0.01; 
C(ICP)=0.035; 
CN=0.00; 
ZZ=0.00 
Zhang et al. 2001;  
Hustert et al. 2001; 
 Dring et al. 2006; 
Bosch et al. 2006; 
Owen et al. 2008; 
Wang et al. 2008; 
Ferreira et al. 2008 
 252 A>G rs1464603 Intron2   C=0.28, AA=0.64; 
C*=0.34; 
SF=0.31; 
SK=0.36; 
AA=0.76, C=0.25, AS=0.40; 
CN=0.41, MY=0.49, IN=0.38 
Zhang et al. 2001; 
Bosch et al. 2006;  
Ho et al. 2006; 
Karlsen et al. 2006; 
King et al. 2007; 
Sandaranaj et al. 2008 
 275 A>G rs144602 Intron2   C*=0.34; 
AA=0.77, C=0.28, AS=0.34; 
CN=0.40, MY=0.47, IN=0.38 
Bosch et al. 2006;  
King et al. 2007; 
Sandaranaj et al. 2008 
 308 A>T  Intron2   AA=0.00, C=0.00, AS=0.03 King et al. 2007 
 2781C>T  Intron2   C=0.01, AA=0.05; 
C*=0.00 
Zhang et al. 2001; 
Bosch et al. 2006 
PXR*5 2904 C>T   Exon3 R98S Loss of DNA binding and 
transactivation in HepG2 cells; 
reduced transactivation of the 
CYP3A4 promoter in response to 
RIF, LCA, UDCA and 
dexamethasone 
J=0.0024 Koyano et al. 2002, 2004; 
 Owen et al. 2008 
 2954 G>C  Intron 3   J=0.0024 Koyano et al. 2002 
 3015 T>G  Intron3   C=0.02, AA=0.09; 
C*=0.06; 
CN=0.09, MY=0.13, IN=0.11 
Zhang et al. 2001; 
Bosch et al. 2006; 
Sandaranaj et al. 2008 
 4274 C>G  Intron3   C*=0.025 Bosch et al. 2006 
PXR*4 4321 G>A   Exon4 R122Q, conserved Reduced affinity in EMSA for 
PXR binding sequence, 
Reduced ligand activation in 
transient transfection assays 
C=0.01, AA=0.0; 
C*=0.00; 
SK=0.00; 
CN=0.00 
Zhang et al. 2001; 
Bosch et al. 2006; 
Karlsen et al. 2006; 
Wang et al. 2008 
PXR*10 G4374A   Exon4 V140M 50 % lower protein in LS174 T 
cells, Increase in basal 
transctivation activity in LS174 T 
cells, reduced induction by rif and 
corticosterone 
C=0.002, AA=0.0; 
CN=0.006; 
C*=0.00; 
CN=0.00 
Husert et al. 2001; 
Lim et al. 2005; 
Bosch et al. 2006; 
Wang et al. 2008 
PXR*6 4399 G>A   Exon4 R148Q similar transactivation as WT J=0.0024; Koyano et al. 2002, 2004; 
  
 
CN=0.00 Wang et al. 2008 
 4418 C>A  Exon4 Q158K The variant gave rise to much 
lower levels of CYP3A4 promoter 
activity in LS174T and HepG2 
cells exposed to the PXR ligands, 
rifampin and paclitaxel; reduced 
transactivation of the CYP3A4 
promoter in response to RIF, LCA, 
UDCA and dexamethasone 
CN=0.022 Lim et al 2005; 
Owen et al. 2008 
PXR*11 4444 A>G   Exon4 D163G Complete loss of basal 
transctivation activity in 
LS174 T cells, reduced induction 
by corticosterone, but promoter 
dependent enhanced induction by 
rif 
C=0.0, AA=0.014 ; 
CN=0.00 
Husert et al. 2001;  
Wang et al. 2008 
 4448 T>C   Exon4  Syn  C=0.01, AA=0.05; 
C*=0.00 
Zhang et al. 2001; 
Bosch et al. 2006 
 4760 G>A  Intron4   C*=0.685; 
CN=0.65, MY=0.54, IN=0.61 
Bosch et al. 2006; 
Sandaranaj et al. 2008 
 5210 C>T  Intron4   C=0.00, AA=0.05 Zhang et al. 2001 
 5458 C>T   Exon5  Syn  C=0.01, AA=0.0; 
C*=0.00; 
ZZ=0.00 
Zhang et al. 2001; 
Bosch et al. 2006; 
Ferreira et al. 2008 
 5611 C>T  Exon5 Syn  C*=0.01 Bosch et al. 2006 
 5761A>G  Intron5   J=0.0073 Koyano et al. 2002 
 6554 A>C rs2472682 Intron5   SF=0.67 Ho et al. 2006 
 7158 C>G rs6784598 Intron5   ES=0.43 Martinez et al. 2007 
 7635 A>G  rs6785049 Intron5  Rif induced intestinal CYP3A4 
protein : GG>AA; Frequency of 
the minor allele is decreased in 
IBD 
C=0.35, AA=0.77;  
IE=0.340 (IBD), IE=0.406 (Controls); 
C*=0.32; 
SK=0.64; 
AA=0.80, =0.33, AS=0.48; 
CN=0.41, MY=0.24, IN=0.54; 
AR=0.37 
Zhang et al. 2001; 
Dring et al. 2006; 
Bosch et al. 2006;  
Karlsen et al. 2006; 
King et al. 2007; 
Sandaranaj et al. 2008; 
Sookian et al. 2010 
 7637 C>T  Intron5   J=0.0024 Koyano et al. 2002 
 7675 C>T rs6797879 Intron5   C=0.04, AA=0.05; 
C*=0.05; 
AA=0.80, C=0.33, AS=0.48 
Zhang et al. 2001; 
Bosch et al. 2006;  
King et al. 2007 
 7683 C>T  Intron5   C=0.01, AA=0.00; 
C*=0.00 
Zhang et al. 2001; 
Bosch et al. 2006 
 7767 G>A   Exon6 Syn  C=0.01, AA=0.05; 
C*=0.00 
Zhang et al. 2001; 
Bosch et al. 2006 
 8055 C>T  rs2276707 Intron6  Rif induced intestinal CYP3A4 
protein : TT, TC>CC 
C=0.15, AA=0.18; I 
E=0.187 (IBD), IE=0.142 (Controls); 
C*=0.16; 
AA=0.20, C=0.39, AS=0.51; 
ES=0.19; 
CN=0.46, MY=0.44, IN=0.25 
Zhang et al. 2001; 
Dring et al. 2006; 
Bosch et al. 2006;  
King et al. 2007; 
Martinez et al. 2007; 
Sandaranaj et al. 2008 
 8224 C>T; rs12721604 Intron7   C= 0.01, AA=0.05; Zhang et al. 2001; 
  
 
8224 C/T/A C*=0.00; 
AA=0.02T 0.00A, C=0.00T 0.08A, 
AS=0.00T 0.00A 
Bosch et al. 2006;  
King et al. 2007 
 8357 C>G  Intron7   C=0.02, AA=0.00; 
C*=0.00 
Zhang et al. 2001; 
Bosch et al. 2006 
PXR*12 8528 G>A  Exon8  A370T Increase in basal transactivation 
activity in LS174T 
cells, reduced induction by Rif and 
corticosterone 
C=0.0, AA=0.016 
 
Husert et al. 2001 
 8555T>G  Exon8 C379G  C*=0.005 Bosch et al. 2006 
PXR*7 8561 C>T   Exon8 R381W Ligand dependent reduced 
transactivation ; reduced 
transactivation of the CYP3A4 
promoter in response to RIF, LCA, 
UDCA and dexamethasone 
J=0.0024 Koyano et al. 2002, 2004; 
Owen et al. 2008 
 8677 G>A  Intron8   C=0.01, AA=0.00; 
C*=0.00 
Zhang et al. 2001; 
Bosch et al. 2006 
 9148T>C rs12721611 Intron8   AA=0.03, C=0.00, AS=0.00 King et al. 2007 
 9811 A>C  Intron8   C*=0.005 Bosch et al. 2006 
PXR*8 9863 A>G   Exon9 I403V Ligand dependent reduced 
transactivation; ; reduced 
transactivation of the CYP3A4 
promoter in response to RIF, LCA, 
UDCA  
J=0.0024 Koyano et al. 
2002, 2004; 
 
 9976 G>A rs3732358 3’UTR   C= 0.00, AA=0.36; 
AA=0.05, C=0.00,AS= 0.02; 
CN=0.005, MY=0.01, IN=0.01 
Zhang et al. 2001;  
King et al. 2007; 
Sandaranaj et al. 2008 
 9987 G>A  3’UTR   J=0.03; 
CN=0.02, MY=0.00, IN=0.00 
Koyano et al. 2002; 
Sandaranaj et al. 2008 
 10058 C>G  3’UTR   C*=0.005 Bosch et al. 2006 
 10331 A>G rs3732359 3’UTR  Heterozygous showed 80% higher 
Oral MDZ clearance compared 
with wt homozygous. 
C*=0.20; 
AA=0.69, C=0.33, AS=0.59; 
CN=0.43, MY=0.34, IN=0.60; 
C=0.77, AA=0.18 
Bosch et al. 2006;  
King et al. 2007;  
Sandaranaj et al. 2008; 
Oleson et al. 2009 
 10461 C>A  rs10511395 3’UTR   C*=0.12; 
AA=0.06, C=0.00, AS=0.10; 
C=0.13, AA=0.07 
Bosch et al. 2006;  
King et al. 2007; ; 
Oleson et al. 2009 
 10477 G>T rs61760364 3’UTR   C=0.01, AA=0.00 Oleson et al. 2009 
 10483 T>C rs3732360 3’UTR  Carries of the Polymorphism 
showed 80%  higher Oral MDZ 
clearance compared with wt 
homozygous. 
C*=0.24; 
AA=0.69, C=0.23,  AS=0.65; 
CN=0.43, MY=0.34, IN=0.60; 
C=0.74, AA=0.18 
Bosch et al. 2006;  
King et al. 2007; 
Sandaranaj et al. 2008; 
Oleson et al. 2009 
 10552 T>G     AA=0.03, C=0.00, AS=0.00 King et al. 2007 
 10620 C>T  rs1054190 3'UTR  Hepatocytes: 6-beta testosterone 
Hydroxylation following Rif: TT, 
TC<CC 
C=0.11, AA=0.14; 
C*=0.08 
SK=0.13; 
AA=0.03, C=0.01, AS=0.00; 
C=0.11, AA=0.00 
Zhang et al. 2001; 
Bosch et al. 2006;  
Karlsen et al. 2006; 
King et al. 2007; 
Oleson et al. 2009 
 10719 A>G rs6438550 3’UTR   C=0.05, AA=0.00; Zhang et al. 2001; 
  
 
C*=0.05 
AA=0.18, C=0.00, AS=0.00; 
CN=0.09, MY=0.21, IN=0.17; 
C=0.05, AA=0.14 
Bosch et al. 2006;  
King et al. 2007; 
Sandaranaj et al. 2008 
Oleson et al. 2009 
 10799 G>A  rs1054191 3'UTR  Hepatocytes: 6-beta-testosterone 
Hydroxylation following Rif: AA, 
AG<GG 
C=0.13, AA=0.14; 
C*=0.12; 
AA=0.06, C=0.05, AS=0.00; 
C=0.11, AA=0.00; 
AR=0.78 
Zhang et al. 2001;  
Bosch et al. 2006;  
King et al. 2007; 
Oleson et al. 2009; 
Sookian et al. 2010 
 10876 C>T  3’UTR   C=0.02, AA=0.00 Oleson et al. 2009 
 11073 C>A  3’UTR   C=0.01, AA=0.00 Zhang et al. 2001 
 11113 G>T  3’UTR   C=0.10, AA=0.00 Oleson et al. 2009 
 11125 A>G rs12721615 3’UTR   C=0.01, AA=0.00; 
C=0.01, AA=0.06 
Zhang et al. 2001; 
Oleson et al. 2009 
 11156 A>C  rs3814057 3’UTR  Intestinal Pgp protein: CC, AC< 
AA 
C=0.16, AA=0.33;  
NL=0.18; 
IE=0.164 (IBD),  IE=0.151 (Controls) 
AA=0.43 , C=0.09,  AS=0.50 ; 
CN=0.46, MY=0.42, IN=0.24; 
CN=0.55; 
C=0.17, AA=0.62; 
ES=0.17 
AR=0.17 
Zhang et al. 2001;  
Op den Buijsch et al. 2005; 
Dring et al. 2006;  
King et al. 2007; 
Sandaranaj et al. 2008; 
Wang et al. 2008; 
Oleson et al. 2009; 
Oliver et al. 2010; 
Sookian et al. 2010 
 11193 T>C  rs3814058 3'UTR  Intestinal Pgp protein: CC, TC< 
TT 
C=0.16, AA=0.30; 
SK=0.16; 
AA=0.54, C=0.14, AS=0.53; 
CN=0.46, MY=0.42, IN=0.24; 
CN=0.55; 
C=0.17, AA=0.62; 
ES=0.17 
Zhang et al. 2001;  
Karlsen et al. 2006; 
King et al. 2007; 
Sandaranaj et al. 2008; 
Wang et al. 2008; 
Oleson et al. 2009; 
Oliver et al. 2010; 
 11255C>T rs2461826 3'UTR   AA=0.04, C=0.00, AS=0.00 King et al. 2007 
 11643G>A  3'UTR   AA=0.24, C=0.00, AS=0.06 King et al. 2007 
 12026 A>G  3'UTR   AA=0.00, C=0.00, AS=0.04 King et al. 2007 
 
Adapted from Lamba et al. 2005: Populations C=Caucasians; C*= population composed of 93% Caucasians; J=Japanese; AA=African-
American; CN=Chinese; IE=Ireland; SF=Scotland; AS= Asians; PDR=Samples from a set of Polymorphism discovery resource purchased from 
Coriell DNA repository; ICP= Intrahepatic cholestasis of pregnancy; ZZ=Zanzibar; SK= Scandinavian; MY=Malay; IN=Indian; 
AR=Argentineans with “self reported” European ancestry ; FR*=French patients with renal transplant; SG*=Singapore (Patients with Breast 
cancer); NL=Netherland; ES=Spain 
IBD=Inflammatory bowel disease 
  
 
APPENDIX2: LIST OF ALL PXR SNPS ANALYSED BY RE-SEQUENCING IN THE VIETNAMESE POPULATION 
      Allele frequency
c
 Genotypic Frequencies
c
 
N
o
 Position
a
 Aminoacid change Identifier Sequence n
b
 wt mut wt/wt wt/mut mut/mut 
1 -25564 G>A   GATAGA[G/A]AAGAAA 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
2 -25385 C>T  rs3814055 CAGGTT[C/T]TCTTTT 75 0.83 
(0.76-0.88) 
0.17 
(0.12-0.24) 
0.69 
(0.58-0.79) 
0.28 
(0.19-0.39) 
0.03 
(0.00-0.10) 
3 -25036 G>C   TGGTCA[G/C]CCTTCT 73 1.00 
 (0.97 - 
1.00) 
0.00  
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
4 -25003 C>T   GGGTCA[C/T]ATTCTC 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
5 - 24910 G>A   TGATTG[G/A]CACCGT 75 0.99 
(0.96-0.99) 
0.01 
(0.00-0.04) 
0.99 
(0.92-0.99) 
0.01 
(0.00-0.08) 
0.00 
(0.00-0.06) 
6 -24756 G>A  rs1523128 AAATGC[G/A]CTCAGA 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
7 -24737
 
A>G   TAGACA[G/A]AGCGGA 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
8 -24719 C>G   GCCACT[C/G]TCTTTC 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
9 -24462 G>A   ACTTCA[G/A]TGGGAA 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
  
 
10   rs2276705 C>A CGGCCT[C/A]AGCCTG 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
11 -24381 A>C  rs1523127 CCTGAA[A/C]AAGGCA 75 0.83 
(0.76-0.88) 
0.17 
(0.12-0.24) 
0.69 
(0.58-0.79) 
0.28 
(0.19-0.39) 
0.03 
(0.00-0.10) 
12   rs7623520 C>T AGGCAG[C/T]GGCTCC 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
13 -23925 C>T   TACCAC[C/T]TCCAAG 56 0.99 
(0.94-1.00) 
0.01 
(0.00-0.05) 
0.98 
(0.89-1.00) 
0.02 
(0.00-0.10) 
0.00 
(0.00-0.08) 
14 -23913 T>G  rs3814056 GGACTG[T/G]GGGAGC 56 0.71 
(0.61-0.78) 
0.29 
(0.22-0.38) 
0.48 
(0.36-0.61) 
0.45 
(0.32-0.58) 
0.07 
(0.02-0.17) 
15 -23700C>T   CTCTAC[C/T[ATTGAA 56 0.00 
(0.00-0.04) 
1.00 
(0.96-1.00) 
0.00 
(0.00-0.08) 
0.00 
(0.00-0.08) 
1.00 
(0.92-1.00) 
16 23G>C S8T  AAGAAA[G/C]CTGGAA 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
17 34G >A A12T rs1063955  AACCAT[G/A]CTGACT 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
18 52 G>A E18K rs59371185 CACTGT[G/A]AGGACA 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
19 79 C>T P27S rs12727613 GGAAAG[C/T]CCAGTG 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
20 106 G>A G36R  GAAGTC[G/A]GAGGTC 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
21 252 A>G  rs1464603 GGTAAC[A/G]TCTCAG 75 0.55 0.45 0.29 0.51 0.20 
  
 
(0.47-0.62) (0.38-0.53) (0.20-0.41) (0.40-0.62) (0.12-0.30) 
22 275 A>G  rs144602 TGACCT[A/G]TCCCCC 75 0.57 
(0.49-0.65) 
0.43 
(0.35-0.51) 
0.32 
(0.23-0.43) 
0.51 
(0.40-0.62) 
0.17 
(0.10-0.28) 
23 308 A>T   TGGCCC[A/T]CCCAAA 75 0.99 
(0.96-1.00) 
0.01 
(0.00-0.04) 
0.99 
(0.92-1.00) 
0.01 
(0.00-0.08) 
0.00 
(0.00-0.06) 
24 2781C>T   GTGCAT[C/T]CCCCCT 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
25 2904 C>T R98S  GCCTGC[C/T]GCCTGC 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
26 2939 G>T N109K rs1140968  GAAGAA[T/G]GAGAGT 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
27 2954 G>C   GCAGTG[G/C]GCGCGC 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
28 3015 T>G   GGTGTG[T/G]GCATGC 61 0.84  
(0.76-0.89) 
0.16 
(0.11-0.24) 
0.74 
(0.62-0.83) 
0.19 
(0.12-0.32) 
0.07 
(0.02-0.16) 
29 4321 G>A R122Q rs12721608 AGAGGC[G/A]GGCCTT 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
30 4374 G>A V140M  CTGGGA[G/A]TGCAGG 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
31 4399 G>A R148Q  AGCAGC[G/A]GATGAT 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
32 4418C>A Q158K  GACGCT[C/A]AGATGA 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
  
 
33 4444A>G D163G  CCTTTG[A/G]CACTAC 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
34 4448T>C Syn rs12721611 TGACAC[T/C]ACCTTC 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
35 5458C>T Syn  CAGTGG[C/T]TGCGAG 67 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.93-1.00) 
0.00 
(0.00-0.07) 
0.00 
(0.00-0.07) 
36 5611 C>T   CAGTGG[C/T]GGGAAA 67 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.93-1.00) 
0.00 
(0.00-0.07) 
0.00 
(0.00-0.07) 
37 5761 A>G   GTGGCC[A/G]GGAGGT 67 0.99 
(0.94-1.00) 
0.01 
(0.00-0.06) 
0.97 
(0.89-1.00) 
0.03 
(0.00-0.11) 
0.00 
(0.00-0.07) 
38 7635 A>G  rs6785049 CCTCTC[A/G]CCCCCA 66 0.41 
(0.33-0.49) 
0.59 
(0.51-0.67) 
0.18 
(0.11-0.29) 
0.45 
(0.34-0.57) 
0.36 
(0.26-0.48) 
39 7637 C>T   TCTCGC[C/T]CCCAAC 
67 
1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.93-1.00) 
0.00 
(0.00-0.07) 
0.00 
(0.00-0.07) 
40 7675C>T  rs6797879 TGCCGG[T/C]CTGTGG 67 0.81 
(0.74-0.87) 
0.19 
(0.13-0.26) 
0.67 
(0.55-0.77) 
0.28 
(0.19-0.40) 
0.04 
(0.01-013) 
41 7683C>T   TGTGGG[C/T]TGCCTC 68 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
42 7737C>T  rs1140969 C>T CTTGCC[C/T]ATCGAG 68 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
43 7767 G>A   GAAGGG[G/A]GCCGCT 68 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
44 7812 T>C  rs4058490  GTTCAA[T/C]GCGGAG 68 0.00 1.00 0.00 0.00 1.00 
  
 
(0.00-0.03) (0.97-1.00) (0.00-0.06) (0.00-0.06) (0.94-1.00) 
45 8055C>T  rs2276707 CTCCAT[C/T]CTGTTA 73 0.60 
(0.52-0.67) 
0.40 
(0.33-0.49) 
0.44 
(0.33-0.55) 
0.31 
(0.22-0.43) 
0.25 
(0.16-0.36) 
46 8118 C>T  
 
Syn (Y) rs2229856C>T CCACTA[C/T]ATGCTG 68 0.74 
(0.66-0.80) 
0.26 
(0.20-0.35) 
0.47 
(0.36-0.59) 
0.53 
(0.41-0.64) 
0.00 
(0.00-0.06) 
47 8528G>A A370T rs35761343 CAATTC[G/A]CCATTA 71 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
48 8555T>G C379G  ATTGAA[T/G]GCAATC 71 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
49 8561C>T R381W  TGCAAT[C/T]GGCCCC 71 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
50 8582T>G   CATAGG[T/G]GAGCAC 70 0.79 
(0.72-0.85) 
0.21 
(0.15-0.28) 
0.59 
(0.47-0.70) 
0.41 
(0.31-0.53) 
0.00 
(0.00-0.06) 
51 8592A>G   CACAGC[A/G]GGGGGT 71 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
52 8677G>A   GCATCT[G/A]GAGGTA 71 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
53 9683A>G I403V  CGCAGC[A/G]TCAATG 60 0.99 
(0.95-1.00) 
0.01 
(0.00-0.05) 
0.98 
(0.90-1.00) 
0.02 
(0.00-0.10) 
0.00 
(0.00-0.07) 
54 9915T>A F420Y  ACCCCT[T/A]TGCTAC 65 0.99 
(0.95-1.00) 
0.01 
(0.00-0.05) 
0.98 
(0.91-1.00) 
0.02 
(0.00-0.9) 
0.00 
(0.00-0.07) 
55      9932C>G Q426 E rs56162473 CTCATG[C/G]AGGAGT 65 0.98 
(0.94-1.00) 
0.02 
(0.00-0.06) 
0.97 
(0.88-1.00) 
0.03 
(0.00-0.11) 
0.00 
(0.00-0.07) 
  
 
56    9976G>A  rs3732358 CCTTGG[G/A]TGACAC 68 0.98 
(0.95-0.99) 
0.02 
(0.00 -0.06) 
0.97 
(0.89-1.00) 
0.03 
(0.00-0.11) 
0.00 
(0.00-0.06) 
57 9987G>A   ACCTCC[G/A]AGAGGC 68 0.99 
(0.96-1.00) 
0.01 
(0.00-0.05) 
0.98 
(0.91-1.00) 
0.02 
(0.00-0.09) 
0.00 
(0.00-0.06) 
58 10058C>G   AAGAGC[C/G]GACAAT 65 0.98 
(0.94-1.00) 
0.02 
(0.00-0.06) 
0.97 
(0.88-1.00) 
0.03 
(0.00-0.11) 
0.00 
(0.00-0.07) 
59 10098 C>T   TTCCTG[C/T]TATGAC 71 0.99 
(0.96-1.00) 
0.01 
(0.00-0.04) 
0.99 
(0.92-1.00) 
0.01 
(0.00-0.08) 
0.00 
(0.00-0.06) 
60 10159 C>G  rs10460826 TTCAGT[C/G]TGTAGG 66 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.93-1.00) 
0.00 
(0.00-0.07) 
0.00 
(0.00-0.07) 
61 10263G>T     CCTGTG[G/T]TCTGGG 66 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.93-1.00) 
0.00 
(0.00-0.07) 
0.00 
(0.00-0.07) 
62 10331A>G  rs3732359 AAGGAT[A/G]GGCCAT 68 0.36 
(0.28-0.44) 
0.64 
(0.56-0.72) 
0.22 
(0.14-0.33) 
0.28 
(0.19-0.40) 
0.50 
(0.38-0.62) 
63 10461 C>A  rs10511395 GGGCTC[C/A]AGGCCT 56 1.00 
(0.96-1.00) 
0.00 
(0.00-0.04) 
1.00 
(0.92-1.00) 
0.00 
(0.00-0.08) 
0.00 
(0.00-0.08) 
64 10477G>T  rs61760364 CTCATC[G/T]GCAGGC 46 1.00 
(0.95-1.00) 
0.00 
(0.00-0.05) 
1.00 
(0.91-1.00) 
0.00 
(0.00-0.09) 
0.00 
(0.00-0.09) 
65 10483 T>C  rs3732360 GGCAGG[C/C]GCATGA 66 0.36 
(0.29-0.45) 
0.64 
(0.55-0.71) 
0.23 
(0.14-0.34) 
0.27 
(0.18-0.39) 
0.50 
(0.38-0.62) 
66 10552 T>G   AGAAGC[T/G]TGGCAT 36 1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
1.00 
(0.88-1.00) 
0.00 
(0.00-0.11) 
0.00 
(0.00-0.11) 
67 10620C>T  rs1054190 AAGCAC[C/T]GATAAT 44 1.00 0.00 1.00 0.00 0.00 
  
 
(0.95-1.00) (0.00-0.05) (0.90-1.00) (0.00-0.10) (0.00-0.10) 
68 10691A>G  rs9851439  GTTTAT[A/G]GTTAAA 44 1.00 
(0.95-1.00) 
0.00 
(0.00-0.05) 
1.00 
(0.90-1.00) 
0.00 
(0.00-0.10) 
0.00 
(0.00-0.10) 
69 10719 A>G  rs6438550 ACAAAC[A/G]ATTTGG 64 0.82 
(0.74-0.88) 
0.18 
(0.12-0.26) 
0.75 
(0.63-0.84) 
0.14 
(0.07-0.25) 
0.11 
(0.05-0.21) 
70 10799 G>A  rs1054191 GATGGC[G/A]GGCACT 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
71 10828 A>G  rs2472683  GTTCCC[A/G[AGGACA 75 0.00 
(0.00-0.03) 
1.00 
(0.97-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
1.00 
(0.94-1.00) 
72 10876 C>T   TGAGTG[C/T]GTGTGT 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
73 10896 G>A  rs34344833 GGTGTA[G/A]GTAGGT 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
74 10988 A>T  rs12107248  AATCAG[A/T]TAAACA 75 0.00 
(0.00-0.03) 
1.00 
(0.97-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
1.00 
(0.94-1.00) 
75 11073 C>A   AAAGTG[C/A]CTGCCT 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
76 11113 G>T   TTTTTT[G/T]CATTTT 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
77 11125 A>G  rs12721615 TCACAA[A/G]TTATAC 75 1.00 
(0.97-1.00) 
0.00 
(0.00-0.03) 
1.00 
(0.94-1.00) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.06) 
78 11156 A>C  rs3814057 CACCTA[A/C]GAACTA 75 0.56 
(0.48-0.64) 
0.44 
(0.36-0.52) 
0.40 
(0.30-0.51) 
0.32 
(022-0.43) 
0.28 
(0.19-0.39) 
  
 
79 11193 T>C  rs3814058 TTAATG[T/C]CAAATC 75 0.56 
(0.48-0.64) 
0.44 
(0.36-0.52) 
0.40 
(0.30-0.51) 
0.32 
(022-0.43) 
0.28 
(0.19-0.39) 
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